

AHA SCIENTIFIC STATEMENT

Cardio-Oncology: Vascular and Metabolic Perspectives

A Scientific Statement From the American Heart Association

ABSTRACT: Cardio-oncology has organically developed as a new discipline within cardiovascular medicine as a result of the cardiac and vascular adverse sequelae of the major advances in cancer treatment. Patients with cancer and cancer survivors are at increased risk of vascular disease for a number of reasons. First, many new cancer therapies, including several targeted therapies, are associated with vascular and metabolic complications. Second, cancer itself serves as a risk factor for vascular disease, especially by increasing the risk for thromboembolic events. Finally, recent data suggest that common modifiable and genetic risk factors predispose to both malignancies and cardiovascular disease. Vascular complications in patients with cancer represent a new challenge for the clinician and a new frontier for research and investigation. Indeed, vascular sequelae of novel targeted therapies may provide insights into vascular signaling in humans. Clinically, emerging challenges are best addressed by a multidisciplinary approach in which cardiovascular medicine specialists and vascular biologists work closely with oncologists in the care of patients with cancer and cancer survivors. This novel approach realizes the goal of providing superior care through the creation of cardio-oncology consultative services and the training of a new generation of cardiovascular specialists with a broad understanding of cancer treatments.

Umberto Campia, MD, MS, FAHA, Chair
Javid J. Moslehi, MD, Vice Chair
Laleh Amiri-Kordestani, MD*
Ana Barac, MD, PhD
Joshua A. Beckman, MD, FAHA
David D. Chism, MD, MS
Paul Cohen, MD, PhD
John D. Groarke, MBBCh, MPH
Joerg Herrmann, MD
Carolyn M. Reilly, PhD, RN, FAHA
Neal L. Weintraub, MD, FAHA
On behalf of the American Heart Association Council on Peripheral Vascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on Cardiovascular and Stroke Nursing

*The contributions of Dr Amiri-Kordestani represent her opinions and not those of the US Food and Drug Administration.

Key Words: AHA Scientific Statements
■ cardiovascular diseases ■ medical oncology ■ therapeutics

© 2019 American Heart Association, Inc.

<https://www.ahajournals.org/journal/circ>

The vascular and metabolic adverse effects of cancer and cancer therapies have spurred the growth of cardio-oncology as a field. Unlike the left ventricular (LV) dysfunction associated with some of the early chemotherapies in oncology,¹ vascular effects are diverse and less well characterized. In this document, we focus on vascular cardio-oncology as a new and significant research and clinical dimension in cardio-oncology. Whereas traditional cancer treatments have been associated with vascular complications in an often-unpredictable fashion, new cancer therapies frequently target the interaction between cancer and the endothelium and may result in predictable vascular and metabolic sequelae. Because of the more clearly defined mechanisms of action, these novel targeted oncology therapies can introduce new paradigms in vascular biology.² At the same time, the intersection of cancer and cardiovascular disease (CVD) extends beyond pharmacology. New data suggest that common risk factors, including genetic factors, can underlie the pathogenesis of cancer and CVD, a paradigm that can have significant public health implications, especially for the >16 million Americans who are cancer survivors.^{3,4} In this document, we highlight these new paradigms in the field of cardio-oncology and bring to the forefront the many unanswered questions and future directions.

VASCULAR COMPLICATIONS OF TRADITIONAL THERAPIES

Despite the advent of targeted cancer agents and immunotherapies, traditional cytotoxic chemotherapies and radiation therapy (RT) remain the cornerstone of many treatment protocols. Vascular complications of these traditional cancer therapies are explored in this section (Table 1).

Antimetabolites

The fluoropyrimidines are important antimetabolites and include 5-fluorouracil (5-FU) and its oral prodrug, capecitabine. These agents are used in the treatment of gastrointestinal, breast, and head and neck tumors. Fluoropyrimidines may cause myocardial ischemia by inducing coronary artery spasm, which may occur in the absence of angiographic coronary artery disease (CAD).⁵ Multiple mechanisms have been reported to underlie vasospasm, including endothelial cell damage with cytolysis and denudation, as well as increased endothelin-1 bioactivity, leading to enhanced contractility of vascular smooth muscle cells and vasoconstriction.^{6–8} The incidence of coronary vasospasm varies by agent and schedule of administration. When high-dose 5-FU-based chemotherapy was given as a continuous intravenous infusion, events consistent with coronary

vasospasm (angina, arrhythmia, or sudden death) were reported in up to 5.4% of patients.⁹ In a prospective cohort, short-term 5-FU and leucovorin administration was associated with the occurrence of cardiac-related events in 2.4% of patients.¹⁰ Vascular toxicity of 5-FU is observed predominantly within 72 hours of the first cycle.¹¹ In a retrospective analysis from the Dutch Colorectal Cancer Group, ischemia/infarction was observed in 2.9% of the patients treated with capecitabine, and the highest incidence of cardiac events was observed in patients treated with capecitabine combined with oxaliplatin and bevacizumab.¹² Symptoms are generally reversible after cessation of the fluoropyrimidine and with the administration of vasodilators. However, despite the reversibility of vasospasm, death can occur.¹¹ There is a high risk of relapse with fluoropyrimidine rechallenge,¹³ and relapse is associated with higher mortality.¹¹ Therefore, rechallenge should be reserved for those without reasonable alternative cancer therapies and should occur only in the context of informed consent, aspirin therapy, vasodilator therapy with L-type calcium channel blockers or nitrates or both, continuous electrocardiographic monitoring (ideally in a coronary care unit), and bolus, rather than continuous, 5-FU infusion.^{14,15} Of note, Clasen and colleagues¹⁶ recently reported that cardioprotective pretreatment with 2 calcium channel blockers (nifedipine and diltiazem) and long-acting isosorbide mononitrate allowed successful rechallenge with bolus intravenous 5-FU or oral capecitabine in 11 patients.

Antimicrotubule Agents (Taxanes and Vinca Alkaloids)

Taxanes cause mitotic arrest and activate caspase-dependent apoptosis through microtubule destabilization.¹⁷ Direct effects on endothelial and smooth muscle cells, which may occur at concentrations below those inducing cytotoxicity, lead to antiangiogenic effects or vascular disruption.^{18–20} Clinical manifestations of vascular toxicity induced by taxanes include peripheral neuropathy mediated by damage to the vasa nervorum,²¹ capillary hyperpermeability with fluid retention,²² and myocardial ischemia.²³ The incidence and severity of these vascular toxicities exhibit a dose-response relationship.²⁴

Vinca Alkaloids

Reported vascular toxicities after exposure to vincristine alone or in combination with other drugs include chest pain,²⁵ myocardial infarction (MI),^{26,27} hypertension,²⁸ Raynaud phenomenon,^{25,29} and thromboembolism.³⁰ Caspase-mediated apoptosis and inhibition of endothelial cell proliferation are implicated in the pathogenesis of these toxicities.²⁴

Table 1. Summary of Main Vascular Toxicities Associated With Traditional Cancer Therapies and Proposed Mechanisms for Toxicities

Cancer Therapy	Proposed Mechanisms of Vascular Toxicity	Vascular Toxicities*
Antimetabolites: fluoropyrimidines	Endothelial injury Vasospasm Increased endothelin-1 bioactivity	Coronary vasospasm Raynaud phenomenon
Antimicrotubule agents: taxanes	Interference with basic endothelial cell functions by affecting the cytoskeleton	Capillary leak Peripheral neuropathy
Antimicrotubule agents: vinca alkaloids (vincristine, vinblastine)	Caspase-mediated apoptosis Inhibition of endothelial cell proliferation	Chest pain presentations Hypertension Myocardial ischemia Raynaud phenomenon Thromboembolism
Alkyl-like agents: platinum compounds	Injury to endothelial cells Increased platelet aggregation Reduced NO availability	Cerebrovascular events Hypertension Myocardial ischemia/MI Raynaud phenomenon Venous thromboembolic disease
Alkylating agents: cyclophosphamide	Injury to endothelial cells Increased platelet aggregation Decreased angiotensin-converting enzyme activity	Cerebrovascular events Hepatic veno-occlusive disease Hypertension Myocardial ischemia/MI Pulmonary hypertension Raynaud phenomenon
Antitumor antibiotics: anthracycline	Production of reactive oxygen species DNA double-stranded breaks Mitochondrial dysfunction Injury to endothelial cells	Endothelial dysfunction
Antitumor antibiotics: bleomycin	Inhibition of endothelial cell proliferation/migration Endothelial cell apoptosis	Myocardial ischemia/MI Pulmonary hypertension Raynaud phenomenon
Other older therapies: IL-2	Cytotoxic effects by lymphokine-activated killer cells Direct effects of IL-2 on endothelial cells Induction of inflammatory cytokines	Vascular leak syndrome

IL indicates interleukin; MI, myocardial infarction; and NO, nitric oxide.

*Vascular toxicities are presented in alphabetical order. Order does not reflect prevalence of respective toxicities.

Alkyl-Like and Alkylating Agents

The platinum compounds such as cisplatin are alkyl-like agents that are associated with Raynaud phenomenon, hypertension, MI, stroke, arterial thrombosis, acute limb ischemia, deep vein thrombosis (DVT), and pulmonary embolism.^{31–34} Furthermore, chest pain has been reported in as many as 38% of patients with testicular cancer treated with cisplatin in combination with vinca alkaloids and bleomycin.²⁵ These adverse events are likely the result of direct toxic effects on endothelial cells, platelet activation, and decreased nitric oxide availability.^{35,36} The alkylating agent cyclophosphamide is associated with a comparable range of vascular adverse effects mediated by similar mechanisms, particularly when used at high doses before bone marrow or stem cell transplantation.^{37–39}

Antitumor Antibiotics

Anthracyclines are cytotoxic antibiotics used for a variety of hematologic and solid malignancies. The risk of anthracycline-induced cardiomyopathy is well recognized and follows a dose-response relationship.^{40–42} In addition to direct cardiomyocyte toxicity through DNA double-stranded breaks (via topoisomerase II), production of reactive oxygen species, and mitochondrial dysfunction,⁴³ anthracyclines may injure the vascular endothelium.^{44,45} Such endothelial toxicity can occur immediately,⁴⁶ and endothelial dysfunction can persist for months to years after exposure.^{45,47} The implications of endothelial dysfunction for the vascular health of anthracycline-treated patients require more investigation, and current clinical practice focuses largely on surveillance for myocardial dysfunction rather than vascular toxicities in this cohort.

Bleomycin, a DNA-damaging chemotherapy drug used in the treatment of lymphomas and head, neck, and testicular cancers, exerts antiangiogenic effects by inhibiting endothelial cell proliferation and migration and by inducing endothelial cell apoptosis.⁴⁸ Bleomycin, alone or in combination with vinca alkaloids, cisplatin, or etoposide, is associated with Raynaud phenomenon,⁴⁹ MI,⁵⁰ and pulmonary hypertension.⁵¹ In particular, bleomycin is associated with a 3-fold increased risk of Raynaud phenomenon among testicular cancer survivors, and this risk is dose related.⁵²

Other Agents

Trastuzumab is a humanized monoclonal antibody that targets the extracellular domain of the HER2 (human epidermal growth factor receptor-2) receptor, and its use has improved cancer outcomes in HER2-positive breast cancer.⁵³ The potential for symptomatic or asymptomatic reductions in LV systolic function is well recognized, and serial assessment of LV function throughout treatment is considered standard of care.^{54,55} In initial trials with trastuzumab, patients were concomitantly treated with anthracyclines, which resulted in considerable risk for cardiomyopathy (up to 27% in an initial trial).⁵³ This risk was attenuated in subsequent trials in which anthracyclines were given before trastuzumab or trastuzumab was used alone without anthracyclines.^{55,56} Less clear with respect to cardiomyopathy risk is the case of dual HER2 blockade (in which newer compounds such as pertuzumab are combined with trastuzumab), although early data suggest cardiomyopathy signals similar to those with trastuzumab monotherapy.^{57,58} The HER2 receptor is also expressed in vascular endothelial cells,⁵⁹ and disruption of the HER2 signaling may contribute to the pathophysiology of myocardial injury.^{60,61}

IL (interleukin)-2 is an immunotherapeutic agent used to treat metastatic melanoma and renal cell carcinoma. Administration of high-dose IL-2 is associated with vascular leak syndrome, a potentially fatal condition of increased vascular permeability in multiple organs leading to pulmonary edema, hypotension, and acute renal and cardiovascular failure.⁶² The pathogenesis of vascular damage in vascular leak syndrome includes cytotoxic effects by lymphokine-activated killer cells,^{63,64} direct effects of IL-2 on endothelial cells,⁶⁵ and induction of inflammatory cytokines such as tumor necrosis factor- α and IL-1.⁶⁵

Radiation Therapy

More than 50% of patients with cancer receive RT during treatment.⁶⁶ Vascular structures within the radiation field are vulnerable to injury.^{67,68} Acute vascular effects of RT include endothelial dysfunction⁶⁹ and infiltration

of inflammatory cells,⁷⁰ which can lead to persistent inflammation and progressive damage to the microvasculature⁷¹ and to conduit arteries.⁷² In addition, radiation injury to the vasa vasorum can precipitate ischemia of the vessel wall.^{73,74} Thoracic RT is associated with an increased risk of premature CAD; it has been observed in Hodgkin lymphoma⁷⁵⁻⁷⁷ and breast cancer^{78,79} survivors. RT to the head and neck confers a significantly increased risk of carotid disease, transient ischemic attack, and ischemic stroke.^{80,81} RT can also cause large- and medium-vessel vasculopathy, as exemplified by axillary artery stenosis after RT to the axilla in patients with breast cancer and porcelain aorta after mediastinal RT.⁸² The nonselective damage to any vascular structures included in the irradiated field is highlighted by reports of radiation-induced DVT,⁸³ venous stenosis,⁸⁴ and renal artery stenosis.⁸⁵ The total cumulative dose is an important risk factor for RT-mediated vascular injury; a linear radiation dose-response relationship with subsequent risk of CAD has been described.^{78,86} Risk from RT also increases over time.^{79,87} Other risk factors for radiation-induced vasculopathy include a higher dose of radiation fractions, young age at time of treatment, concomitant cancer therapies, and superficial location of vessels.^{76,88} Radiation-induced vasculopathy may occur in the absence of traditional risk factors. Follow-up of patients at risk of radiation-induced vasculopathy should include careful longitudinal assessment for signs and symptoms of vascular disease and optimization of modifiable cardiovascular risk factors.

In addition to vascular damage, cranial, neck, and mediastinal radiation can cause impaired autonomic regulation of the cardiovascular system and can result in labile blood pressure, labile heart rate, and orthostatic intolerance.⁸⁹⁻⁹² In a study that compared 263 Hodgkin lymphoma survivors clinically referred for exercise treadmill testing after a median interval of 19 years (interquartile range, 12–26 years) after mediastinal radiation with 526 matched controls, survivors of mantle radiation had an almost 4 times higher likelihood of elevated resting heart rate and a >5 times higher likelihood of abnormal heart rate recovery after cessation of exercise in adjusted analyses.⁹¹ These autonomic abnormalities increased in prevalence with time from RT and were associated with significant reductions in exercise performance. Furthermore, abnormal heart rate recovery was associated with a 4-fold increased risk of all-cause mortality during follow-up of survivors of mediastinal radiation.

For patients receiving mediastinal RT, some expert groups have proposed that periodic surveillance with functional noninvasive stress testing for CAD detection should be performed starting 5 to 10 years after treatment and continued every 5 years thereafter.^{88,93} Similarly, ultrasound scanning of the carotid arteries for patients treated with prior neck RT has also been

suggested.^{88,93,94} Management of coronary, carotid, or other vascular disease in the aftermath of RT is based largely on data extrapolated from nonradiation cohorts. Outcomes after percutaneous coronary intervention⁹⁵ and cardiac surgery^{96,97} among patients receiving RT are worse compared with those in nonradiation cohorts, and carotid interventions are associated with higher rates of in-stent restenosis.⁹⁸ However, the reported data are from retrospective, observational, or nonrandomized studies, and randomized controlled trials are needed to investigate outcomes in these patients. Refinements in contemporary radiation protocols that include lower cumulative radiation doses, cardiac shielding, tangential fields, 3-D image-guided treatment planning, and respiratory gating have successfully reduced incidental radiation exposure to cardiovascular structures.^{99–102} It is hoped that such refinements will reduce subsequent risk of CVD.

VASCULAR COMPLICATIONS WITH TARGETED THERAPIES

The introduction of targeted cancer therapies has significantly augmented the arsenal of treatment options for patients with cancer. By targeting specific signaling pathways that are hijacked by the cancer cell, these therapies have resulted in the introduction of precision medicine in the clinic and in the improvement of patient outcomes. For example, the realization that, in many cancers, kinases become inappropriately active has fostered the development of kinase inhibitors as a therapeutic strategy.¹⁰³ In particular, small-molecule kinase inhibitors, which may be administered orally, have shown efficacy for multiple cancer types and have dramatically changed the natural history of several malignancies. In chronic myelogenous leukemia (CML), for example, recognition of activation of ABL1 (Abelson murine leukemia viral oncogene homolog 1) kinase driven by a specific chromosomal translocation (the so-called Philadelphia chromosome) allowed specific therapeutic targeting. The introduction of imatinib, the first of several such small-molecule inhibitors, significantly improved outcomes in patients with CML, effectively transforming it into a chronic disease.^{104,105}

In many cases, kinases and their downstream pathways that are usurped by the cancer cell also play critical roles for vascular and metabolic homeostasis in normal cells.² Inhibitors of these kinases may cause cardiovascular sequelae, depending on the individual compound and the specific kinase target (Table 2). For example, inhibition of the vascular endothelial growth factor (VEGF) signaling pathway results in hypertension, proteinuria, cardiomyopathy, and vascular disease in a subset of patients.¹⁰⁶ Dasatinib, nilotinib, and ponatinib, new-generation ABL1 kinase inhibitors used for

the treatment of CML, are associated with pulmonary hypertension (dasatinib), hyperglycemia and atherosclerosis (nilotinib), and hypertension and vascular disease (ponatinib).¹⁰⁷ The most concerning vascular toxicities that may occur with the new agents include arterial ischemic events such as MI, stroke, and limb ischemia, as well as venous thromboembolic (VTE) events.¹⁴

VEGF inhibitors, which include both biologics (eg, bevacizumab, a monoclonal antibody targeting circulating VEGF) and small-molecule inhibitors targeting VEGF receptors, lead to increased blood pressure within days to a week of starting therapy, resulting in hypertension in at least a quarter of patients. The level of variation in the observed blood pressure response and in the criteria used to define systemic hypertension in clinical practice and clinical trials has bestowed a wide range of incidence estimates. Despite this uncertainty, it is well documented that newer VEGF inhibitors can result in hypertension in an even larger percentage of patients, in some cases >50%.¹⁰⁸ For example, treatment-induced hypertension has recently been reported in 57% of antineoplastic-naïve patients with metastatic renal cell carcinoma newly started on pazopanib.¹⁰⁹ VEGF is a critical growth and survival factor for endothelial cells and exerts important homeostatic functions. Inhibition of VEGF signaling may elevate blood pressure by reducing the bioavailability of nitric oxide, a pivotal vasodilator and antithrombotic and anti-inflammatory molecule, and by increasing the activity of the potent vasoconstrictor peptide endothelin-1. In addition, it can lead to capillary rarefaction, resulting in increased resistance in the microcirculation.¹¹⁰ Other proposed mechanisms of VEGF inhibitor-associated hypertension include a rightward shift of the renal pressure–natriuresis curve, impaired sodium excretion with consequent fluid retention, and salt-dependent hypertension.^{110,111} On the basis of this evidence, the association between VEGF inhibitors and hypertension is not surprising; however, the best antihypertensive approach remains undefined. In the absence of a directly tested protocol for the management of VEGF inhibitor-related hypertension, general practice includes the avoidance of the calcium channel blockers diltiazem and verapamil because of the risk of drug–drug interaction related to the induction of CYP3A4 and the preferred use of angiotensin-converting enzyme inhibitors and the dihydropyridine calcium channel blocker amlodipine.¹¹² Of note, angiotensin-converting enzyme inhibitors have been associated with superior outcomes in patients with renal cell cancer in small studies.^{113,114}

Recent reports indicate that VEGF inhibitor therapy might lead to adverse vascular events, including aortic dissection,¹¹⁵ stroke,^{116,117} and arterial and venous thrombosis. Bevacizumab is associated with the highest incidence of VTE among VEGF inhibitors, with VTEs occurring in nearly 12% of patients¹¹⁸ compared with 2%

Table 2. Summary of Main Vascular Toxicities Associated With Targeted Therapies and Proposed Mechanisms for Toxicities

Cancer Therapy	Proposed Mechanisms of Vascular Toxicity	Vascular Toxicities*
Antibody-related targeted therapies: VEGF-A monoclonal antibody (bevacizumab), VEGF-R2 monoclonal antibody (ramucirumab), VEGF-R1/R2 fused to Fc portion of IgG1 (aflibercept)	Reduction of PI3K-Akt, PLC γ -PKC/IP3, and Erk-MAPK signaling pathway activity in endothelial cells with reduction in eNOS activity, NO production, endothelial function, and cell survival and proliferation (capillary rarefaction) Increase in mitochondrial oxidative stress and eNOS uncoupling, reducing NO bioavailability	Cerebrovascular events Myocardial ischemia/MI Proteinuria Renal thrombotic microangiopathy Reversible posterior leukoencephalopathy syndrome Systemic hypertension Venous thromboembolic disease
Tyrosine kinase-related targeted therapies: primarily VEGF-R directed Sorafenib Sunitinib Pazopanib Axitinib Regorafenib Cabozantinib Vandetanib Lenvatinib	Reduction of PI3K-Akt, PLC γ -PKC/IP3, and Erk-MAPK signaling pathway activity in endothelial cells with reduction in eNOS activity, NO production, endothelial function, and cell survival and proliferation (capillary rarefaction) Increase in mitochondrial oxidative stress and eNOS uncoupling, reducing NO bioavailability Increase in endothelin-1 production Rightward shift of the renal pressure–natriuresis curve, impaired sodium excretion, fluid retention, and salt-dependent hypertension Inhibition of PDGF β -R signaling and pericyte function and survival with reduced VEGF and Ang-1 production and reduced VEGF-R and Tie-2 signaling activity in endothelial cells	Cerebrovascular events Myocardial ischemia/MI Proteinuria Renal thrombotic microangiopathy Systemic hypertension Venous thromboembolic disease Reversible posterior leukoencephalopathy syndrome
Tyrosine kinase-related targeted therapies: primarily ABL directed Nilotinib Ponatinib Dasatinib	Reduction in endothelial cell c-Abl signaling and cell survival Reduction in VEGF-R2 signaling with reduction in endothelial function, survival, and proliferation	Cerebrovascular events Myocardial ischemia/MI Pulmonary hypertension (especially dasatinib) Systemic hypertension (especially ponatinib) Venous thromboembolic disease
Proteasome inhibitors (bortezomib, carfilzomib)	Induction of vascular oxidative stress Endothelial dysfunction and injury Inhibition of endothelial cell proliferation	Cerebrovascular events Myocardial ischemia/MI Systemic and pulmonary hypertension Venous thromboembolic disease
Immunomodulatory agents (thalidomide, lenalidomide)	Inhibition of endothelial cell migration Induction of homeostatic imbalance	Cerebrovascular events Myocardial ischemia/MI Systemic hypertension Venous thromboembolic disease
Immune checkpoint inhibitors: ipilimumab (CTLA-4), nivolumab (PD-1), pembrolizumab (PD-1), atezolizumab (PD-L1), avelumab (PD-L1), durvalumab (PD-L1)	Activation of immune cells (T cells)	Myocarditis (vasculo-mediated) Vasculitis

ABL indicates Abelson murine leukemia viral oncogene homolog; Ang-1, angiopoietin 1; CTLA-4, cytotoxic T lymphocyte–associated protein 4; eNOS, endothelial nitric oxide synthase; Erk, extracellular signal–regulated kinase; Ig, immunoglobulin; IP3, inositol trisphosphate; MAPK, mitogen-activated protein kinase; MI, myocardial infarction; NO, nitric oxide; PDGF β -R, platelet-derived growth factor- β receptor; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; PKC, protein kinase C; PLC γ , phosphoinositide phospholipase C γ ; Tie-2, tyrosine kinase with Ig and endothelial growth factor homology domains type 2; VEGF, vascular endothelial growth factor; and VEGF-R, vascular endothelial growth factor receptor.

*Vascular toxicities are presented in alphabetical order. Order does not reflect prevalence of respective toxicities.

to 6% of patients treated with VEGF receptor tyrosine kinase inhibitors.¹⁰⁸ Nearly half of these events are high-grade VTEs, defined as thrombotic episodes leading to clinical events, medical interventions, or death.

The vascular toxicity associated with small molecules inhibiting VEGF may also contribute to the cardiomyopathy observed with these agents. For example, the earliest drugs approved in this class, sunitinib, sorafenib, and pazopanib, which target other angiogenic kinase receptors such as platelet-derived growth factor receptors, were associated with the occurrence

of cardiomyopathy.^{119–122} Mouse models of VEGF inhibitor–associated cardiomyopathy suggest that these drugs may lead to capillary rarefaction in the myocardium, subsequent myocyte hypoxia, and induction of hypoxia-inducible factors, which is sufficient to cause a reversible cardiomyopathy.^{123–126} Consistent with these models, the cardiomyopathy seen with sunitinib and sorafenib is often reversible.^{119,127} Although additional research is needed, these data suggest a mechanistic linkage between vascular and myocardial pathologies and the general contribution of the former to myocar-

dial disease both in cardio-oncology and in other forms of heart disease.²

There are intriguing similarities between vascular toxicities associated with VEGF inhibitors and pregnancy-associated CVD.² As in preeclampsia, proteinuria often accompanies hypertension in patients treated with VEGF inhibitors.¹²⁸ Patients may also have evidence of thrombotic angiopathy on renal biopsy, similar to patients with severe preeclampsia.¹²⁹ Emerging evidence that pregnancy-related CVD (including peripartum cardiomyopathy) is at least partly caused by VEGF inhibition (via placental secretion of sFLT-1 [soluble fms-like tyrosine kinase 1], a soluble splice variant of the VEGF receptor that functions as a decoy receptor) provides biological plausibility of a common underlying mechanism.^{2,130,131} The above observations also suggest that cardiovascular sequelae that arise as a result of VEGF inhibitors are probably the result of “on-target” effects.

Whereas vascular toxicities seen with VEGF inhibitors may be expected (and even predicted) on the basis of the underlying biology, the spectrum of vascular sequelae of kinase inhibitors targeting ABL1 in patients with CML has been surprisingly broad. Imatinib, the first kinase inhibitor in this class, has a safe clinical profile, and some data suggest a vascular protective effect.^{107,132} In contrast, nilotinib is associated with peripheral and coronary artery events.^{14,107,108} A single-center observation of the occurrence of ankle-brachial index reductions in patients treated with nilotinib suggests atherosclerosis as the main pathophysiological mechanism.¹³³ Ponatinib, a third-generation kinase inhibitor for CML and the only drug active against a number of resistant CML subtypes, is associated with significant peripheral and coronary artery ischemic events. The severity of these events led to transient withdrawal of drug approval by the US Food and Drug Administration (FDA).¹⁰⁷ Dasatinib has been associated with pulmonary hypertension and a slightly higher incidence of MI and stroke compared with imatinib.^{134,135} The diverse vascular effects of kinase inhibitors in CML suggest that these toxicities are likely dissociable from the cancer target (in this case, the ABL1 kinase) and suggest “off-target” vascular effects.¹⁰⁷

Other classes of novel oncology therapies work through different mechanisms but are associated with significant vascular disease. Immunomodulators such as thalidomide and lenalidomide and proteasome inhibitors such as carfilzomib target the cellular protein degradation machinery and have been highly effective for a number of B-cell malignancies, including multiple myeloma.¹³⁶ Immunomodulators are associated with the occurrence of thromboembolic events, which occur predominantly in the venous circulation and in patients receiving concomitant multiagent chemotherapy and dexamethasone.¹³⁶ The prothrombotic effect could be extrinsic, arising from stimulation of the coagulation cas-

cade consequent to endothelial injury. Alternatively, *in vitro* data support the hypothesis that thalidomide and lenalidomide induce a hypercoagulable state through increased endothelial tissue factor expression; that is, stimulation of the intrinsic coagulation pathway.¹³⁷ The mechanisms for the increased risk of thrombotic events with thalidomide and its analogs are ill-defined. For clinical practice, risk factors have been identified that enable a practical approach within the framework of 3 risk categories.¹³⁸ Patients on single-agent thalidomide (or thalidomide analogs) are at low risk (<5%) and do not require prophylaxis. Patients with no or 1 risk factor who are not receiving multiagent chemotherapy or high-dose dexamethasone are at standard risk (up to 20%) and should receive prophylaxis with aspirin (81 mg/d may suffice). Patients with ≥ 2 risk factors and any patient receiving multiagent chemotherapy or high-dose dexamethasone are considered high risk and should receive prophylaxis with either warfarin or low-molecular-weight heparin (LMWH).¹³⁸

In the past 2 decades, immune checkpoint inhibitors have emerged as one of the most revolutionary paradigms in cancer therapy. The best known of these are monoclonal antibodies that block CTLA-4 (cytotoxic T lymphocyte-associated protein 4) and PD-1 (programmed cell death protein 1) T-lymphocyte receptor pathways, thus activating the immune system.¹³⁹ Drugs such as ipilimumab (targeting CTLA-4) or nivolumab and pembrolizumab (targeting PD-1) have produced durable regressions in patients with a widening spectrum of malignancies.¹⁴⁰ Vascular events (specifically vasculitis) have been described in a number of recent case reports in patients treated with immune checkpoint inhibitors.^{141,142} Fulminant myocarditis has been described as a rare toxicity associated with these therapies.^{143,144} Given the explosion of these therapies for all cancer types, alone and in combination with other cancer agents with known vascular toxicity, it will be important to monitor patients for the occurrence of cardiovascular events and to better define the specific toxicities associated with these therapies.

The immune system may be harnessed in other ways to fight cancer. For example, there has been considerable interest in chimeric antigen receptor (CAR)-modified T cells. Broadly, this personalized therapeutic approach involves removal of the patient's T cells, followed by *in vitro* activation, genetic modification, and infusion of the cells back into the patient. Recently, autologous anti-CD19 CAR T-cell therapy showed considerable efficacy in patients with refractory large B-cell lymphoma and acute B-cell lymphoblastic leukemia.^{145,146} The main adverse event after the infusion of CAR T cells is the onset of the cytokine release syndrome, characterized by immune activation with elevated inflammatory cytokines, including interferon- γ , granulocyte macrophage colony-stimulating factor, IL-10, and IL-6.¹⁴⁷ It is too

early to determine whether cardiovascular complications are a concern with CAR T-cell treatment, although vascular leak syndrome with hypotension, QT prolongation, tachycardia and other arrhythmias, troponin elevation, and LV systolic dysfunction have been reported in small subsets of patients.¹⁴⁴

METABOLIC COMPLICATIONS OF CANCER THERAPIES

The link between metabolic dysregulation and CVD has been under investigation for decades. Abnormalities in glucose and lipid levels and increased blood pressure are key elements of the metabolic syndrome. Increased levels of each of these components are associated with increased rates of CVD.¹⁴⁸ Thus, it should not be surprising that therapies that adversely affect metabolism may also be associated with cardiac and vascular sequelae. The use of androgen deprivation in prostate cancer serves as a good example. Androgen deprivation therapy (ADT) has been used to treat this hormone-sensitive malignancy for decades and is accepted as front-line therapy.¹⁴⁹ In 2006, using a large population-based study of older men, Keating and colleagues¹⁵⁰ demonstrated that ADT, in the form of gonadotropin-releasing hormone agonism, was associated with a significantly increased risk of incident diabetes mellitus, CAD, MI, and sudden cardiac death by 44%, 16%, 11%, and 16%, respectively. Further retrospective studies confirmed these results, again using real-world populations.^{151,152} On the other hand, data from randomized oncology clinical trials demonstrated that ADT increased mortality only in patients with underlying CAD or heart failure (HF).^{153–156} In exploring the mechanisms of these adverse cardiovascular events, multiple studies have shown that ADT increased insulin resistance and the rate of incident diabetes mellitus.^{150,151,157–161} ADT has also been shown to consistently increase total cholesterol and low-density lipoprotein levels and to have mixed effects on high-density lipoprotein levels.^{162–166} Despite the largely adverse changes in metabolism, endothelial function is preserved or enhanced with ADT.^{167,168} Moreover, the changes in metabolism and vascular function return to baseline on ADT cessation.¹⁶⁹

Because cancer itself represents a dysregulation of metabolism to promote cell growth and survival, it should not be surprising that metabolism has become a therapeutic target. In many cases, these targets also play critical roles in normal metabolic homeostasis. For example, PI3Ks (phosphoinositide 3-kinases) are lipid kinases that mediate response to insulin. The PI3K pathway is also frequently altered in cancer; small-molecule inhibitors targeting PI3K or immediate downstream targets have been introduced at a rapid pace, and several

have already been approved for specific cancer types. Not surprisingly, glucose can be affected by PI3K inhibition because upregulation of the glucose transporter, *glut4*, occurs in part through insulin-mediated PI3K activation.¹⁷⁰ Copanlisib, which is indicated for the treatment of adults with relapsed follicular lymphoma who have received at least 2 prior systemic therapies, is commonly associated with hyperglycemia.^{171–174} Although glucose dysregulation as a result of PI3K inhibitors may be expected, metabolic abnormalities resulting from other novel therapies may suggest new targets for scientific study. Small-molecule inhibitors that target VEGF and platelet-derived growth factor signaling pathways (eg, sunitinib and sorafenib) seem to improve glycemia.^{175–179} In some instances, agents used to treat the same malignancy have opposite effects on glycemia. Such is the case in the treatment of CML. Imatinib improves glycemia, whereas nilotinib can worsen it.^{180–184} Taken together, these findings indicate more complex pharmacological effects or regulation of metabolism by these agents than is currently appreciated. In addition, they emphasize the need for increased clinical vigilance when novel therapeutic agents are applied.

THROMBOTIC COMPLICATIONS IN CANCER AND ITS TREATMENT

Venous thrombosis, including superficial thrombophlebitis, DVT, in-dwelling catheter-associated thrombosis, and pulmonary embolism, likely represents the most common cardiovascular complication of malignancy. In a Dutch series of 3220 consecutive patients with a first DVT or pulmonary embolism, the presence of malignancy increased the rate of VTE 7-fold compared with patients without cancer.¹⁸⁵ In this series, hematologic malignancies increased the odds ratio of VTE 28-fold, whereas both lung and gastrointestinal tumors increased the odds >20-fold. In a Danish study of 57 951 patients with cancer and 287 476 individuals in a general population cohort, cancer increased the risk of VTE 8-fold.¹⁸⁶ The risk of developing VTE was highest (15-fold) in the first year after diagnosis. As would be expected, the presence of metastases, particularly at distant sites, also increases the VTE risk (Figure 1).¹⁸⁷ In a large Californian cancer registry, for various types of malignancy, the 2-year cumulative incidence of VTE increased with progression of the disease from localized to regional to remote.¹⁸⁸ Patients with cancer represent ≈20% of the overall VTE burden, and the annual incidence in these patients is 0.5% compared with 0.1% in the general population.¹⁸⁹ Despite a stable background population rate of VTE, the incidence of cancer-associated VTE is increasing over time.¹⁸⁷




Figure 1. Two-year incidence of venous thromboembolism (VTE) by type and spread of cancer.

Modified from Timp et al¹⁸⁷ with permission of the American Society of Hematology; permission conveyed through Copyright Clearance Center, Inc. Copyright © 2013, American Society of Hematology.

Thrombosis in patients with cancer is also characterized by a particularly high clot burden. Imberti and colleagues¹⁹⁰ have demonstrated that the rates of bilateral lower extremity DVT, ilio caval thrombosis, and upper limb DVT were elevated in patients with cancer compared with patients without cancer. Furthermore, patients with cancer have significantly increased rates of VTE recurrence. In a study of 840 patients with DVT, individuals with cancer had an $\approx 21\%$ recurrence rate at 1 year compared with $\approx 7\%$ in the patients without malignancy.¹⁹¹ In the RIETE registry (Registro Informatizado de Enfermedad TromboEmbólica), which included nearly 19 000 subjects, the relative risk of recurrence was 2.4-fold for DVT and 2-fold for pulmonary embolism.¹⁹² As discussed in the next paragraph, the high rate of recurrence has led to recommendations for extended or indefinite anticoagulation. Louzada and colleagues¹⁹³ developed a clinical prediction rule for recurrent VTE with cancer-associated thrombosis. The authors identified 4 predictors: sex, primary tumor site, stage, and

Table 3. Ottawa Score for Recurrent Venous Thromboembolism in Cancer-Associated Thrombosis

Variable	Points
Female	1
Lung cancer	1
Breast cancer	-1
TNM stage 1	-2
Previous VTE	1
Clinical probability	
Low (≤ 0)	-3 to 0
High (≥ 1)	1 to 3

TNM indicates tumor, node, and metastases; and VTE, venous thromboembolism.

Modified from Louzada et al¹⁹³ with permission. Copyright © 2012, American Heart Association, Inc.

prior VTE (Table 3). The score had a 100% sensitivity, a 98.1% negative predictive value, and a negative likelihood ratio of 0.16. Scores ranged from -3 to 3 ; a score of ≤ 0 indicated a risk of $<4.5\%$, whereas a score of ≥ 1 was associated with a risk of recurrence of 19%. The score was validated in 2 randomized controlled trials of anticoagulation in cancer-associated VTE. The development of a VTE event is a poor prognostic sign in a patient with malignancy. Patients with cancer-associated VTE have an increased risk of bleeding compared with patients with cancer without VTE. Worse, cancer-associated VTE confers a significantly increased risk of death. In a Norwegian study of 740 patients and a first VTE, mortality was 5-fold higher in patients with cancer compared with those without cancer.¹⁹⁴ In the RIETE registry, the risk was 6-fold.¹⁹⁵ Even within a cancer-only population, VTE increases the rate of death from 1.6- to 4.2-fold.¹⁸⁸ Causality is often not easy to establish, and there is no recommendation for routine VTE prophylaxis in cancer outpatient practice except for patients with multiple myeloma (as outlined in the Vascular Complications With Targeted Therapies section).

The presence of cancer changes the duration of therapy of VTE and requires the use of specific drugs. Because of the increased risk of recurrence, the American College of Chest Physician guidelines recommend "extended anticoagulant therapy (no scheduled stop date)" even in the presence of a high bleeding risk.¹⁹⁶ Three randomized clinical trials have compared LMWH therapy with vitamin K antagonism with an international normalized ratio target of 2.0 to 3.0. Both dalteparin and enoxaparin showed superiority in the prevention of recurrent VTE compared with vitamin K antagonism therapy.^{197,198} As a result of these 2 clinical trials, LMWH is the preferred therapy at this time; however, limiting factors include costs, the need for long-term injections, and the inability to easily reverse the effects. The reduction of recurrent VTE in a study comparing tinzaparin with vitamin K antagonism trended toward better outcomes with LMWH, but it did not reach statistical significance.¹⁹⁹ Over the past decade, direct oral anticoagulants (DOACs) have become a standard therapy in the management of VTE. A meta-analysis of the large approval trials of DOACs showed preliminary evidence that these agents are as effective and safe as conventional treatment for the prevention of VTE in patients with cancer.²⁰⁰ More recently, the first 2 of several trials of DOACs in a cancer population have been published. In a study of 1050 patients with cancer and acute VTE, participants were randomized to dalteparin or edoxaban for 6 to 12 months.²⁰¹ The primary outcome, recurrent VTE or major bleeding, was met by 12.8% of the subjects randomized to dalteparin or 13.5% of the subjects who received edoxaban ($P=0.006$ for noninferiority). In a pilot study, the risk of recurrent VTE in cancer patients

was lower with rivaroxaban compared with dalteparin (HR, 0.43 [95% CI, 0.19–0.99]). However, the risk of clinically relevant non-major bleeding was higher with rivaroxaban than with dalteparin (HR, 3.76 [95% CI, 1.63–8.69]).^{201a} A study comparing apixaban with dalteparin has been presented in abstract form. Treatment with apixaban was associated with a significantly lower rate of VTE recurrence compared with dalteparin (3.4% vs 14.1%, respectively; HR, 0.26 [95% CI, 0.09–0.80]; $P=0.0182$) with superior quality of life and very low bleeding rates.^{201b} Finally, the Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients clinical trial (NCT02583191; comparing rivaroxaban with standard LMWH therapy) is currently ongoing.

From the accumulating evidence, it is likely that in the near future oral DOAC therapy may become a standard therapy for cancer-associated VTE, but several caveats apply, including the impact of renal and liver dysfunction on dosing, drug-drug interactions, and the problem of reversing anticoagulation effects.

COMMON RISK FACTORS BETWEEN CANCER AND CVD

An area in need of further exploration in cardio-oncology has emerged from the growing evidence that common risk factors can predispose to both cancer and CVD.²⁰² Notably, data from the ARIC study (Atherosclerosis Risk in Communities) indicate that adherence to the 7 American Heart Association 2020 Strategic Impact Goal cardiovascular health metrics is inversely associated not only with CVD but also with cancer, most strongly breast, colorectal, and lung cancer.²⁰³ Some risk factors (eg, tobacco) have a well-known association with certain cancer types (eg, lung cancer) and CVD.²⁰⁴ More recently, other cardiovascular risk factors have also emerged as potentially important risk factors in cancer. For example, epidemiological data suggest that hyperlipidemia can serve as a risk factor for estrogen receptor–positive breast cancer.²⁰⁵ Data from the Canadian National Cancer Surveillance System study suggest that postmenopausal women within the top quartile of dietary cholesterol intake had a 48% increase in the risk of breast cancer.²⁰⁶ Mechanistically, 27-hydroxycholesterol, a cholesterol metabolite, may serve as the biochemical link between lipid metabolism and cancer. 27-Hydroxycholesterol can act as a direct estrogen receptor agonist in breast cancer cells, thus stimulating the growth and metastatic spread of tumors in several models of breast cancer.²⁰⁷ Alternatively, a growing body of literature suggests that inflammation is a risk for both cancer and CVD. For example, the recent results of CANTOS (Canakinumab Antiinflammatory Thrombosis

Outcome Study) showed that pharmacological inhibition of IL-1 β reduced both cardiac events and lung cancer incidence and mortality.^{208,209}

Genetic risk factors have also emerged as important common risk factors for cancer and CVD. Clonal hematopoiesis of indeterminate potential, which is defined as the presence of an expanded somatic blood cell clone in individuals without other hematologic abnormalities, is common in older populations and is associated with an increased risk of hematologic cancer.^{210,211} Surprisingly, clonal hematopoiesis of indeterminate potential also serves as risk factor for MI, stroke, and all-cause mortality in this population.²¹⁰ Clonal hematopoiesis of indeterminate potential results from an expansion of cells that harbor an initiating driver mutation, with frequent somatic mutations in 3 genes: *DNMT3A*, *ASXL1*, and *TET2*.^{210,211} Mutations in these 3 genes are each individually associated with coronary heart disease, and basic models suggest that these genes may participate in the pathogenesis of atherosclerosis.^{212,213}

These common links between cancer and CVD have enormous public health implications.²⁰² For example, the link between cholesterol and breast cancer provides the rationale for the clinical evaluation of pharmacologic approaches that interfere with cholesterol/27-hydroxycholesterol synthesis (ie, a statin) as a means to mitigate breast cancer pathogenesis. These observations may be particularly relevant to cancer survivors. The >16 million American cancer survivors are at risk of 2 major diseases that contribute to morbidity and early mortality: recurrence of their cancer and CVD. The ability to address these patients' cardiovascular risks may have the added advantage of protecting them from cancer recurrence. In addition, identifying new risk factors such as genetic risks may inform new approaches to preventing and treating both conditions in this population. The relevance of the intersection between CVD and cancer is being increasingly recognized within the cardiovascular community, as highlighted in a recent scientific statement from the American Heart Association,²¹⁴ which should serve to stimulate much-needed research in this area.

CARDIO-ONCOLOGY RESEARCH DIRECTIONS

The major change in cancer treatment has involved a shift from nonselective toxins to therapies aimed at specific pathways important for cancer growth and survival. These therapeutic options have expanded through investigation of the pathways involved in tumorigenesis. These pathways often play critical roles in cardiovascular homeostasis and may exert effects on the heart and vasculature. As the number of small-

molecule kinase inhibitors, which can target multiple kinases, expands, it will be important to define the “off-target” kinase effects of these therapies to better predict possible toxicities when these agents are being tested in humans.^{215,216} Understanding the vascular sequelae of new targeted cancer therapies also offers an opportunity for basic and translational investigations in which pathways critical for vascular signaling may be uncovered.² Consequently, robust programs in cardio-oncology engage in a multidisciplinary approach in which cardiovascular and oncology teams informed of the most recent research findings closely collaborate to scrutinize for new vascular sequelae and strive to tailor therapies accordingly. Recent primary prevention studies in patients with breast cancer receiving anthracyclines or HER2-targeted therapies point out the limitations of a “universal prevention” (or “wide-gun”) approach such as the use of either β -blockers or angiotensin-converting enzyme inhibitors in all patients undergoing breast cancer treatment.^{217–220} There is a critical unmet need to develop personalized, risk-based approaches based on a detailed knowledge of the underlying pathophysiology.

Further collaboration with basic and translational scientists will permit investigations to elucidate the mechanism of the toxicities and to define patients at risk, such that preventive and treatment efforts can be focused on these high-risk patients. As the field of cardio-oncology matures, integration of basic and translational research teams will be needed to most efficiently define the cardiovascular implications of new therapies, to elucidate the mechanisms of toxicity, and to develop management strategies for patients.²¹⁵ More robust basic and translational research models, however, will be needed to determine the mechanisms of toxicity. In cardiomyocyte biology, the introduction of induced pluripotent stem cells differentiated into cardiomyocytes offers a human-based platform on which cardiac toxicity can be modeled.²²¹ Differentiation of induced pluripotent stem cells into endothelial cells and smooth muscle cells could likewise enable modeling of vascular toxicity. In addition, induced pluripotent stem cells can be derived from individual patients with or without clinical toxicity, which could further advance the personalized approach²²¹ and help to define vascular and metabolic mechanisms of toxicity (Table 4).

An example of rigorous clinical observations leading to basic and mechanistic insights is the early reports of cardiomyopathy after treatment with small-molecule kinase inhibitors targeting VEGF and platelet-derived growth factor receptors.^{120,121} From these clinical observations, several mouse models were created that demonstrated the contribution of impaired vascular function to the cardiomyopathy. One such model involved a mouse expressing a “tunable” transgene

Table 4. Future Research Directions in Vascular Cardio-Oncology

More rigorous identification of cardiovascular and cardiometabolic side effects during clinical trials and in the real-world population after drug approval
Cardiovascular adjudications by an independent committee during clinical trials
Multi-institutional registries for identifying vascular and metabolic toxicities once a drug is approved
Open-source data sharing among pharmaceutical companies with cardiovascular toxicities of cancer therapies
Comprehensive and systematic vascular phenotyping via biomarkers and imaging
Personalized/precision medicine in cardio-oncology
Better identification of patients at risk for cardiovascular toxicities during cancer treatment
Single integrated registry with researchers, patients, providers, and clinical diagnostic laboratories entering family history, clinical and research data, and accompanying biospecimens (including DNA) in a deidentified manner
Genetic inquiries for risk of toxicity
Development of better vascular imaging and use in cardio-oncology population
Integration of basic, translational, and clinical research programs in academic cardio-oncology
Cardiovascular clinical and translational models to help elucidate mechanisms of toxicity
Development of more robust model cell systems (eg, induced pluripotent stem cells) and animal models for preclinical testing of novel compounds
Research on mechanisms of common risk factors (including genetic risk factors) that are shared between cancer and cardiovascular disease
Education of clinicians and patients about cardiovascular toxicities of cancer therapies
Web-based platforms for access to known vascular toxic effects of novel anticancer drugs

encoding a VEGF trap, recapitulating the effects of bevacizumab. In this mouse model, the induction of the VEGF trap leads to decreased myocardial capillary density (capillary rarefaction), induction of hypoxia and hypoxia-inducible genes in the myocardium, and cardiac dysfunction, which is reversible on removal of the transgene.¹²³ Similarly, mice in which PDGF (platelet-derived growth factor) receptor β is genetically deleted in the heart exhibited decreased capillary density, increased myocardial hypoxia, and accentuated HF after transverse aortic constriction.^{124,222} Both of these models resulted in myocardial hypoxia leading to the stabilization and activation of the master transcriptional factor hypoxia-inducible factor and induction of hypoxia-inducible factor–regulated genes. Chronic stabilization of hypoxia-inducible factor proved sufficient to lead to cardiomyopathy in mice.^{125,126} Although it remains to be seen whether myocardial hypoxia resulting from VEGF inhibitor–mediated capillary rarefaction plays a causal role in cardiomyopathy in humans, pre-

clinical models predict that the cardiomyopathy is reversible and more consistent with myocardial hibernation rather than necrosis, which is consistent with early clinical observations.^{119,127}

HOW TO STRUCTURE A CARDIO-ONCOLOGY SERVICE

Although much has been written about the need for a cardio-oncology service to provide comprehensive cardiovascular care to patients with cancer and cancer survivors, the actual components and structure of such a service have not been established. In many instances, cardiology consultative services for preoperative cancer surgery assessment or management of symptomatic CVD such as ischemia, arrhythmia, and HF occurring during cancer treatment serve as a focal point for home-grown programs. With the growth of new cancer therapeutics and unprecedented improvement in life expectancy in many patients with cancer, there is an unmet need to develop and implement cardiovascular care across the cancer treatment continuum. This approach requires dynamic recognition and management of cardiovascular care needs before, during, and after cancer treatment and effective integration of cardiac and oncology health teams.

Components of Cardio-Oncology Service

A critical theme of the cardio-oncology service is active collaboration and partnership between cardiovascular and oncology teams. Different models have been proposed, mostly reflecting differences in individual cancer programs, from comprehensive National Cancer Institute–designated sites and tertiary referral centers to community-based oncology offices.^{223,224} These programs share the common premise

of multidisciplinary collaboration among medical and radiation oncologists, hematologists, surgeons, palliative care specialists, pharmacists, and cardiologists (including cardiovascular imaging, HF, interventional cardiology, electrophysiology, and more recently, vascular medicine subspecialties). The complexity and heterogeneity of the cardio-oncology team reflect not only the recognition of new cardiovascular effects of cancer therapy but also advances in cardiovascular treatment such as new anticoagulation approaches, interventional strategies for thrombotic complications of cancer and its treatments, cardioprotective and vasculoprotective strategies, transcatheter valve replacement, and arrhythmia management that may offer specific advantages to patients with cancer. Because a single cardio-oncology service model is unlikely to meet these diverse needs, we highlight the examples proposed by Snipelisky and colleagues²²³ and summarize the key elements to consider in program development.

Definition of Need, Content, and Scope of Cardio-Oncology Service

Cardiovascular manifestations in the oncology population span a spectrum of conditions (Figure 2), and the initial step in collaboration requires identification of the individual site priorities along the continuum of cancer treatment. Primary prevention in this field is often defined as cardiovascular care before cancer treatment and may include optimization of existing cardiovascular risk factors and CVD, as well as risk stratification based on the planned cancer management. The recent American Society of Clinical Oncology clinical practice guideline provides a useful tool to standardize identification of patients at risk for cardiac dysfunction²²⁵ (although the document pertains primarily to patients with cardiomyopathy from anthracyclines and HER2-targeted therapies). Timeliness of cardiovascular evaluation, particularly in high-risk patients, is of utmost importance in




Figure 2. Cardiovascular (CV) complications in the oncology population and comprehensive cardio-oncology services across the cancer treatment continuum.

DVT indicates deep vein thrombosis; HER2, human epidermal growth factor receptor-2; TKI, tyrosine kinase inhibitor; and VSP, vascular endothelial growth factor signaling pathway inhibitors.

this patient group and in patients undergoing therapy. Development of new conditions or progression of previous cardiovascular conditions during cancer treatment requires urgent attention. Prompt access to cardiovascular imaging and intervention should be anticipated, and coordination of respective services should be established. Examples of common conditions include acute ischemic and thrombotic events, symptomatic HF, and arrhythmias, which may present in the setting of systemic illness, as adverse effects of treatment, or concurrently with cancer progression. Although the majority of cancer care occurs in the outpatient setting, this group of patients may be more likely to need hospitalization and require coordination of cardio-oncology with inpatient services.

Another distinct area of need is long-term cardiac follow-up for patients undergoing cancer treatment for more indolent malignancies such as CML or metastatic solid tumors with long survivorship such as breast cancer. At the present time, there are limited recommendations for longitudinal cardiovascular surveillance after treatment with anthracyclines and HER2-targeted therapies (monitoring of LV systolic function) and VEGF inhibitors (monitoring of hypertension) has been completed,²²³ reflecting the gap in knowledge and the need for further research in this area. Cardio-oncology services have a unique opportunity to contribute to developing evidence for multidisciplinary approaches to diagnosing and treating complex phenotypes of cardiovascular toxicities.

Cancer survivorship is another growing area in which cardiovascular needs are being recognized, with the projected number of cancer survivors reaching 20 million by 2026 in the United States.²²⁶ In 2006, the Institute of Medicine issued a statement on the need to improve the quality of care of cancer survivors and the importance of individual survivorship care plans stating goals of care, surveillance recommendations, symptoms monitoring, and health maintenance goals.²²⁷ At the present time, recommendations for cardiovascular screening in asymptomatic individuals remain limited to survivors who received therapeutic radiation⁸⁸ or received anthracycline-based regimen as part of childhood and adolescent cancer⁴⁰ or adult cancer treatment.²²⁴

Structure and Institutional Support

The structure of the cardio-oncology service will be determined by the individual oncology programs and resulting patient needs, as well as the resources available. In addition to identification of the content and patient population of interest, considerations need to include staffing and location of cardio-oncology clinics, coordination of care, and institutional support. Different models have been proposed, including (1) a clinic staffed by a cardiologist with communication to oncology practices, (2) a clinic staffed by an oncologist with commu-

nication to cardiology, and (3) a truly multidisciplinary approach with the clinic staffed by oncology, cardiovascular, and often other specialists.²²³ The last model fosters interactions; however, it is resource intensive and may be limited to centers with large volumes. Models 1 and 2 reflect the fact that "ownership" of cardio-oncology services may reside in either specialty as long as expertise and built-in mechanisms for communication are available. The advantages of locating outpatient cardio-oncology clinics within a cancer center include easy patient access and facilitated interactions with oncology services; however, the availability of onsite cardiac imaging and subspecialized cardiovascular services will likely be limited. On the other hand, the alternative model of cardio-oncology clinics within cardiovascular centers may limit access to different oncology specialists and hamper direct communications that promote efficient decision making.⁴⁰ As the field of cardio-oncology evolves, novel model systems of care will be necessary to address these challenging problems.

With recent emphasis on survivorship care, new models of comprehensive cancer survivorship services are emerging, centered mostly within oncology centers and led by nurse practitioners or physician assistants.²²⁸ These programs will offer an important opportunity for the identification of cardiovascular needs and development of pathways for further integration of cardiovascular services into survivorship care. Institutional support is an essential component for the development and sustainability of cardio-oncology services. As cardio-oncology expands as a field, the development of metrics of success will be important to ensure efficiency and quality of care.²²⁹

Continued Integration, Education, and Training

The creation of an integrated multidisciplinary approach and focus on patient care have been identified as essential components of a cardio-oncology service (Figure 3). In 2015, a cardio-oncology survey by the




Figure 3. Integrated multidisciplinary approach and focus on patient care, research (basic, translational, clinical, and population science), education, and clinical training.

CV indicates cardiovascular. Modified from Barac et al²²⁹ with permission from the American College of Cardiology Foundation. Copyright © 2015, American College of Cardiology Foundation.

American College of Cardiology identified the lack of national guidelines and funding as the main barrier to growth and expansion of cardio-oncology programs, followed by limitations in infrastructure, interest, and educational opportunities.²³⁰ In <3 years, progress has been made in several key areas. Recent examples include FDA Public Workshops dedicated to this topic²³¹ and National Institutes of Health research funding announcements focused on improving outcomes in cancer treatment–related cardiotoxicity,²³² which are critical developments that will foster the growth of cardio-oncology. Several multidisciplinary professional society guidelines and statements have been published in a span of <2 years addressing the intersection between CVD and cancer care.^{40,214,233} These comprehensive documents have increased the educational resource base for providers focused on the cardiovascular needs and care of oncology populations and have spurred mainstream educational sessions in cardio-oncology at major scientific meetings. The need for dedicated cardio-oncology training within both specialties has been recognized, and the opportunity to implement and disseminate training will further define centers of excellence in cardio-oncology.

In summary, the operational considerations of a cardio-oncology service include full engagement by the healthcare team to provide patient-centered care approaches; proximity of necessary services and providers; timely scheduling of diagnostic studies with prompt care on the basis of results; timely communication of changes in cancer treatment plans and changes in cardiovascular status; patient education and engagement; and enhanced clinical flow with physician extenders for routine follow-up and preventive care. The need to aggressively address modifiable lifestyle factors cannot be overstated, with an emphasis on referral to cardiac rehabilitation, dietitians, exercise physiologists, and lifestyle education as required.

ROLE OF THE CARDIO-ONCOLOGY FELLOWSHIP

As the field of cardio-oncology matures, there will be a need for more formal training to better prepare the next generation of physicians for what has emerged as a new discipline in cardiology. Cardio-oncology initially emerged as an HF specialty given the toxicities of older agents such as anthracyclines and trastuzumab. However, in 2019, cardio-oncology is truly a general cardiology specialty, and a successful cardio-oncology training program will need to incorporate all elements of a cardiology division, including vascular medicine. Although several institutions have started cardio-oncology fellowship programs, there is a need to better define what makes up a comprehensive fellowship and thus compe-

tency in the field. In the coming years, a formal training paradigm in the model of the Core Cardiovascular Training Statement will need to be developed like the one created for vascular medicine training more than a decade ago.²³⁴

BENCHMARKS AND PUBLIC REPORTING OF NOVEL THERAPIES

Whereas a robust research program in cardio-oncology is critical for better mechanistic understanding of approved cancer therapies, oncology clinical trials offer the opportunity to detect vascular and metabolic toxicities. Oncology clinical trial end points serve different purposes. In conventional drug development, early-phase clinical trials evaluate safety, whereas later-phase studies primarily evaluate whether a drug provides a clinical benefit. In general, the FDA recommends at least 2 adequate and well-controlled clinical trials. However, for drugs approved to treat patients with a malignancy, evidence from 1 trial may be sufficient. Clinical benefits that supported drug approval have included important primary outcomes (eg, increased survival, symptomatic improvement) and effects on established surrogate end points. The accelerated-approval regulations permit the use of surrogate end points for the approval of drugs or biological products that are intended either to treat serious or life-threatening diseases or to demonstrate an improvement over available therapy, particularly when no proven therapy exists. In the case of accelerated approval, the manufacturer is expected to conduct clinical studies to verify and characterize the actual clinical benefit. Although the FDA may grant accelerated approval based on the effects of a surrogate end point that is “reasonably likely” to predict clinical benefit, it may lack sufficient information about the risk of the drug to appropriately articulate it in the labeling. In such a case, the FDA can mandate a postmarketing study or establishment of a registry to collect data as a postmarketing requirement. An observational pharmacoepidemiological study can also be designed with input from the FDA to identify serious risks associated with a drug exposure, to quantify the risks, or to evaluate factors that affect the risk of toxicity such as drug dose, timing of exposure, and patient characteristics. Data sources for observational studies can include administrative healthcare claims data, electronic medical records, prospectively collected observational data, and registries. Some registries are required either before or after drug approval by the FDA as part of Risk Evaluation and Mitigation Strategies. When part of a Risk Evaluation and Mitigation Strategy, these registries are considered essential for drug safety and are not designed as a study with

completion dates. The FDA can require a Risk Evaluation and Mitigation Strategy if the agency determines that safety measures are needed beyond the professional labeling to ensure that the benefits of a drug outweigh its risks.

Because of these measures implemented by the FDA, vascular and metabolic complications may arise after the introduction of new therapies and lead to changes in their use. As an example, ponatinib is the only tyrosine kinase inhibitor effective against many resistant cases of CML. On the basis of encouraging early results of the phase 2 PACE trial (Ponatinib for Chronic Myeloid Leukemia [CML] Evaluation and Ph+ Acute Lymphoblastic Leukemia [ALL]), the FDA granted ponatinib an accelerated approval in 2012.²³⁵ Updated safety information from the PACE trial in late 2013 showed the occurrence of arterial and venous thrombosis and occlusions in at least 27% of patients treated with ponatinib.²³⁶ The sponsor temporarily withdrew ponatinib from the market, and the FDA allowed reintroduction of marketing with implementation of revised labeling, a Risk Evaluation and Mitigation Strategy program, and additional post-marketing safety requirements. Nevertheless, existing data from the ponatinib trial gave very little insight into the mechanisms of vascular toxicity.²³⁷ Whether these cases represent atherosclerotic events, thromboembolic events, or some other vascular process such as vasospasm is unclear. These distinctions are critical because cardiovascular specialists may approach each condition differently in terms of both prevention and treatment. Cases such as the one with ponatinib argue for possible cardiovascular adjudication in oncology trials by an independent committee. Furthermore, similar to the recent emphasis on CVD end points in the approval of medications for diabetes mellitus, stricter oversight for adverse cardiovascular events in the approval process may be warranted. A number of strategies and checklists have been proposed to detect cardiovascular safety signals with cancer drugs early and in a more standardized manner.²³⁸

CONCLUSIONS

The remarkable advances in the understanding of cancer biology have led to breakthrough treatments and an ever-growing number of cancer survivors. This progress has come with both new challenges and unexpected discoveries that have blurred the border

between oncology and cardiovascular medicine. Traditional and new cancer treatments, including several targeted therapies, are associated with vascular injury and metabolic complications. These untoward effects increase the short- and long-term risk of cardiovascular events above and beyond the already elevated risk often present in patients with cancer and cancer survivors. An improved understanding of the mechanisms of toxicity of these therapies may lead to the identification of novel targets to reduce vascular complications while providing biological insights into cardiovascular pathophysiology and informing new platforms for drug discovery. Clinically, optimal management of patients with cancer and cancer survivors is best addressed by a multidisciplinary approach whereby cardiovascular medicine specialists work closely with oncologists to assess cardiovascular risk, to minimize vascular toxicity, and to manage long-term adverse effects. This multidisciplinary approach will require the creation of cardio-oncology services and the training of a new generation of cardiovascular specialists with a broad understanding of cancer treatments.

ARTICLE INFORMATION

The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.

This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on August 6, 2018, and the American Heart Association Executive Committee on October 23, 2018. A copy of the document is available at <http://professional.heart.org/statements> by using either "Search for Guidelines & Statements" or the "Browse by Topic" area. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.

The American Heart Association requests that this document be cited as follows: Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, Cohen P, Groarke JD, Herrmann J, Reilly CM, Weintraub NL; on behalf of the American Heart Association Council on Peripheral Vascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on Cardiovascular and Stroke Nursing. Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association. *Circulation*. 2019;139:e579–e602. doi: 10.1161/CIR.0000000000000641.

The expert peer review of AHA-commissioned documents (eg, scientific statements, clinical practice guidelines, systematic reviews) is conducted by the AHA Office of Science Operations. For more on AHA statements and guidelines development, visit <http://professional.heart.org/statements>. Select the "Guidelines & Statements" drop-down menu, then click "Publication Development."

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at <https://www.heart.org/permissions>. A link to the "Copyright Permissions Request Form" appears in the second paragraph (<https://www.heart.org/en/about-us/statements-and-policies/copyright-request-form>).

Disclosures

Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Umberto Campia	Brigham and Women's Hospital-Harvard Medical School	None	None	None	None	None	None	None
Javid J. Moslehi	Vanderbilt University Medical Center	Bristol-Myers Squibb†; NIH (R56 HL141466)†; Pfizer†	None	None	None	None	Bristol-Myers Squibb*; Ipsen*; Myokardia*; Novartis*; Pfizer*; Regeneron*; Takeda*	None
Laleh Amiri-Kordestani	FDA	None	None	None	None	None	None	None
Ana Barac	Medstar Heart and Vascular Institute, Medstar Washington Hospital Center	Genentech (serves as a cardiology PI on an investigator-initiated study supported by Genentech)*	None	None	None	None	None	None
Joshua A. Beckman	Vanderbilt University	Bayer (DSMB)†; Novartis (DSMB)*	None	None	None	None	AstraZeneca*; Boehringer Ingelheim*; Bristol Myers Squibb*; Merck*; Sonofi*	None
David D. Chism	Vanderbilt University Medical Center	None	None	None	None	None	None	None
Paul Cohen	Rockefeller University Laboratory of Molecular Metabolism	None	None	None	None	None	None	None
John D. Groarke	Brigham and Women's Hospital	Amgen†	None	None	None	None	None	None
Joerg Herrmann	Mayo Clinic Rochester	Amgen†	None	None	None	None	None	None
Carolyn M. Reilly	Emory University School of Nursing	None	None	None	None	None	None	None
Neil L. Weintraub	Medical College of Georgia at Augusta University	NIH (AR070029, HL134354, HL126949, HL142097)†	None	None	None	None	None	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

*Modest.

†Significant.

Reviewer Disclosures

Reviewer	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Geoffrey D. Barnes	University of Michigan	BMS/Pfizer†	None	None	None	None	BMS/Pfizer*; Jansen*	None
Michael Fradley	University of South Florida	None	None	None	None	None	Novartis*	None
Eric H. Yang	University of California at Los Angeles	None	None	None	None	None	Voluntis*	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10 000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

*Modest.

†Significant.

REFERENCES

- Ky B, Vejpongpa P, Yeh ET, Force T, Moslehi JJ. Emerging paradigms in cardiomyopathies associated with cancer therapies. *Circ Res*. 2013;113:754–764. doi: 10.1161/CIRCRESAHA.113.300218
- Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ. Cardio-oncology: how new targeted cancer therapies and precision medicine can inform cardiovascular discovery. *Circulation*. 2015;132:2248–2258. doi: 10.1161/CIRCULATIONAHA.115.010484
- Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “silver tsunami”: prevalence trajectories and comorbidity burden among older cancer survivors in the United States. *Cancer Epidemiol Biomarkers Prev*. 2016;25:1029–1036. doi: 10.1158/1055-9965.EPI-16-0133
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin*. 2018;68:7–30. doi: 10.3322/caac.21442
- Luwaert RJ, Descamps O, Majois F, Chaudron JM, Beauduin M. Coronary artery spasm induced by 5-fluorouracil. *Eur Heart J*. 1991;12:468–470.
- Südhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U, Schmiegel W. 5-Fluorouracil induces arterial vasoconstrictions. *Ann Oncol*. 2004;15:661–664.
- Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. *Cancer Res*. 1993;53:3028–3033.
- Thyss A, Gaspard MH, Marsault R, Milano G, Frelin C, Schneider M. Very high endothelin plasma levels in patients with 5-FU cardiotoxicity. *Ann Oncol*. 1992;3:88.
- de Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, Canal P, Chevreau C, Carrié D, Soulié P. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. *J Clin Oncol*. 1992;10:1795–1801. doi: 10.1200/JCO.1992.10.11.1795
- Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. *J Cancer Res Clin Oncol*. 2008;134:75–82. doi: 10.1007/s00432-007-0250-9
- Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. *Expert Opin Drug Saf*. 2009;8:191–202. doi: 10.1517/14740330902733961
- Kwakman JJ, Simkens LH, Mol L, Kok WE, Koopman M, Punt CJ. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group. *Eur J Cancer*. 2017;76:93–99. doi: 10.1016/j.ejca.2017.02.009
- Becker K, Erckenbrecht JF, Häussinger D, Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. *Drugs*. 1999;57:475–484. doi: 10.2165/00003495-199957040-00003
- Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, Toutouzias K, Leeser MA, Grines CL, Marmagkiolis K. Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. *Circulation*. 2016;133:1272–1289. doi: 10.1161/CIRCULATIONAHA.115.018347
- Dalzell JR, Abu-Arafah A, Campbell RT. Cardiotoxicity with 5-fluorouracil based agents: rechallenge cannot currently be safely advised. *Am J Cardiol*. 2013;111:454. doi: 10.1016/j.amjcard.2012.09.006
- Clasen SC, Ky B, O’Quinn R, Giantonio B, Teitelbaum U, Carver JR. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. *J Gastrointest Oncol*. 2017;8:970–979. doi: 10.21037/jgo.2017.09.07
- Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. *Ann Oncol*. 1994;5:495–505.
- Schwartz EL. Antivascular actions of microtubule-binding drugs. *Clin Cancer Res*. 2009;15:2594–2601. doi: 10.1158/1078-0432.CCR-08-2710
- Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Tarabozetti G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. *Clin Cancer Res*. 1996;2:1843–1849.
- Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge GW Jr. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonist by endothelial growth factors. *Cancer Res*. 2001;61:3369–3372.
- Tofthagen C, McAllister RD, Visovsky C. Peripheral neuropathy caused by paclitaxel and docetaxel: an evaluation and comparison of symptoms. *J Adv Pract Oncol*. 2013;4:204–215.
- Béhar A, Pujade-Lauraine E, Maurel A, Brun MD, Chauvin FF, Feuillade de Chauvin F, Oulid-Aissa D, Hille D. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. *Br J Clin Pharmacol*. 1997;43:653–658.
- Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of Taxol. *J Clin Oncol*. 1991;9:1704–1712. doi: 10.1200/JCO.1991.9.9.1704
- Soulati A, Mountziros G, Avgerinou C, Papaxoinis G, Pectasides D, Dimopoulos MA, Papadimitriou C. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. *Cancer Treat Rev*. 2012;38:473–483. doi: 10.1016/j.ctrv.2011.09.002
- Stefenelli T, Kuzmits R, Ulrich W, Glogar D. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. *Eur Heart J*. 1988;9:552–556.
- Lejonc JL, Vernant JP, Macquin J, Castaigne A. Myocardial infarction following vinblastine treatment. *Lancet*. 1980;2:692.
- Subar M, Muggia FM. Apparent myocardial ischemia associated with vinblastine administration. *Cancer Treat Rep*. 1986;70:690–691.
- Stoter G, Koopman A, Vendrik CP, Struyvenberg A, Sleyfer DT, Willemse PH, Schraffordt-Koops H, van Oosterom AT, ten Bokkel Huinink WW, Pinedo HM. Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin. *J Clin Oncol*. 1989;7:1099–1104. doi: 10.1200/JCO.1989.7.8.1099
- Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud’s phenomenon: a common toxicity after combination chemotherapy for testicular cancer. *Ann Intern Med*. 1981;95:288–292.
- Clarke CS, Otridge BW, Carney DN. Thromboembolism: a complication of weekly chemotherapy in the treatment of non-Hodgkin’s lymphoma. *Cancer*. 1990;66:2027–2030.
- Numico G, Garrone O, Dongiovanni V, Silvestris N, Colantonio I, Di Costanzo G, Granetto C, Occeilli M, Fea E, Heouaine A, Gasco M, Merlano M. Prospective evaluation of major vascular events in patients with non-small cell lung carcinoma treated with cisplatin and gemcitabine. *Cancer*. 2005;103:994–999. doi: 10.1002/cncr.20893
- Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. *Ann Intern Med*. 1986;105:48–51.
- Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, Soff G, Parameswaran R, Hassoun H. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. *J Clin Oncol*. 2011;29:3466–3473. doi: 10.1200/JCO.2011.35.5669
- Abdel-Razeq H, Mansour A, Abdulelah H, Al-Shwayat A, Makoseh M, Ibrahim M, Abunasser M, Rimawi D, Al-Rabaiah A, Alfara R, Abufara A, Ibrahim A, Bawaliz A, Ismael Y. Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! *Thromb J*. 2018;16:2. doi: 10.1186/s12959-018-0161-9
- Nuver J, De Haas EC, Van Zweeken M, Gietema JA, Meijer C. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. *Oncol Rep*. 2010;23:247–253.
- Daher IN, Yeh ET. Vascular complications of selected cancer therapies. *Nat Clin Pract Cardiovasc Med*. 2008;5:797–805. doi: 10.1038/ncpcardio1375
- Cazin B, Gorin NC, Laporte JP, Gallet B, Douay L, Lopez M, Najman A, Duhamel G. Cardiac complications after bone marrow transplantation: a report on a series of 63 consecutive transplantations. *Cancer*. 1986;57:2061–2069.
- Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. *J Clin Oncol*. 1991;9:1215–1223. doi: 10.1200/JCO.1991.9.7.1215
- Goldberg MA, Antin JH, Guinan EC, Rapoport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. *Blood*. 1986;68:1114–1118.
- Armenian SH, Hudson MM, Mulder RL, Chen MH, Constone LS, Dwyer M, Nathan PC, Tissing WJ, Shankar S, Sieswerda E, Skinner R, Steinberger J, van Dalen EC, van der Pal H, Wallace WH, Levitt G, Kremer LC; International Late Effects of Childhood Cancer Guideline Harmonization Group. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncol*. 2015;16:e123–e136. doi: 10.1016/S1470-2045(14)70409-7

41. Lipshultz SE, Franco VI, Miller TL, Colan SD, Sallan SE. Cardiovascular disease in adult survivors of childhood cancer. *Annu Rev Med*. 2015;66:161–176. doi: 10.1146/annurev-med-070213-054849
42. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. *N Engl J Med*. 1991;324:808–815. doi: 10.1056/NEJM199103213241205
43. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. *J Am Coll Cardiol*. 2014;64:938–945. doi: 10.1016/j.jacc.2014.06.1167
44. Ulu N, Buikema H, van Gilst WH, Navis G. Vascular dysfunction in adriamycin nephrosis: different effects of adriamycin exposure and nephrosis. *Nephrol Dial Transplant*. 2008;23:1854–1860. doi: 10.1093/ndt/gfm911
45. Chow AY, Chin C, Dahl G, Rosenthal DN. Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. *J Clin Oncol*. 2006;24:925–928. doi: 10.1200/JCO.2005.03.5956
46. Duquaine D, Hirsch GA, Chakrabarti A, Han Z, Kehrer C, Brook R, Joseph J, Schott A, Kalyanaraman B, Vasquez-Vivar J, Rajagopalan S. Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase. *Vasc Med*. 2003;8:101–107. doi: 10.1191/1358863x03vm4760a
47. Dengel DR, Ness KK, Glasser SP, Williamson EB, Baker KS, Gurney JG. Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia. *J Pediatr Hematol Oncol*. 2008;30:20–25. doi: 10.1097/MPH.0b013e318159a593
48. Mabeta P, Pepper MS. A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents. *Angiogenesis*. 2009;12:81–90. doi: 10.1007/s10456-009-9134-8
49. Singh S, De Trafford JC, Baskerville PA, Martin JF. Response of digital arteries to endothelium dependent and independent vasodilators in patients with Raynaud's phenomenon. *Eur J Clin Invest*. 1995;25:182–185.
50. van den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, ten Bokkel Huinink WW, Rodrigus PT, Schimmel EC, Aleman BM, van Leeuwen FE. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. *J Clin Oncol*. 2006;24:467–475. doi: 10.1200/JCO.2005.02.7193
51. Van Rheen Z, Fattman C, Domarski S, Majka S, Klemm D, Stenmark KR, Nozik-Grayck E. Lung extracellular superoxide dismutase overexpression lessens bleomycin-induced pulmonary hypertension and vascular remodeling. *Am J Respir Cell Mol Biol*. 2011;44:500–508. doi: 10.1165/rcmb.2010-0065OC
52. Glendenning JL, Barbachano Y, Norman AR, Dearnaley DP, Horwich A, Huddart RA. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. *Cancer*. 2010;116:2322–2331. doi: 10.1002/cncr.24981
53. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med*. 2001;344:783–792. doi: 10.1056/NEJM200103153441101
54. Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, Rath V, Fehrenbacher L, Brufsky A, Azar CA, Flynn PJ, Zapas JL, Polikoff J, Gross HM, Biggs DD, Atkins JN, Tan-Chiu E, Zheng P, Yothers G, Mamounas EP, Wolmark N. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. *J Clin Oncol*. 2012;30:3792–3799. doi: 10.1200/JCO.2011.40.0010
55. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med*. 2011;365:1273–1283. doi: 10.1056/NEJMoa0910383
56. Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolane SM. Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer. *JAMA Oncol*. 2016;2:29–36. doi: 10.1001/jamaoncol.2015.3709
57. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. *Lancet Oncol*. 2012;13:25–32. doi: 10.1016/S1470-2045(11)70336-9
58. Lenihan D, Suter T, Brammer M, Neate C, Ross G, Baselga J. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. *Ann Oncol*. 2012;23:791–800. doi: 10.1093/annonc/mdr294
59. Odiete O, Hill MF, Sawyer DB. Neuregulin in cardiovascular development and disease. *Circ Res*. 2012;111:1376–1385. doi: 10.1161/CIRCRESAHA.112.267286
60. Hedhli N, Dobrucki LW, Kalinowski A, Zhuang ZW, Wu X, Russell RR 3rd, Sinusas AJ, Russell KS. Endothelium-derived neuregulin is an important mediator of ischaemia-induced angiogenesis and arteriogenesis. *Cardiovasc Res*. 2012;93:516–524. doi: 10.1093/cvr/cvr352
61. Hedhli N, Huang Q, Kalinowski A, Palmeri M, Hu X, Russell RR, Russell KS. Endothelium-derived neuregulin protects the heart against ischemic injury. *Circulation*. 2011;123:2254–2262. doi: 10.1161/CIRCULATIONAHA.110.991125
62. Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. *Immunopharmacology*. 1997;37:117–132.
63. Assier E, Jullien V, Lefort J, Moreau JL, Di Santo JP, Vargaftig BB, Lapa e Silva JR, Thèze J. NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome. *J Immunol*. 2004;172:7661–7668.
64. Damle NK, Doyle LV. IL-2-activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers: implications for vascular leak syndrome. *J Immunol*. 1989;142:2660–2669.
65. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. *Proc Natl Acad Sci USA*. 1999;96:3957–3962.
66. Cutter DJ, Darby SC, Yusuf SW. Risks of heart disease after radiotherapy. *Tex Heart Inst J*. 2011;38:257–258.
67. Piedbois P, Becquemin JP, Blanc I, Mazeron JJ, Lange F, Mellièrè D, Le Bourgeois JP. Arterial occlusive disease after radiotherapy: a report of fourteen cases. *Radiother Oncol*. 1990;17:133–140.
68. Basavaraju SR, Easterly CE. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. *Med Phys*. 2002;29:2391–2403. doi: 10.1118/1.1509442
69. Beckman JA, Thakore A, Kalinowski BH, Harris JR, Creager MA. Radiation therapy impairs endothelium-dependent vasodilation in humans. *J Am Coll Cardiol*. 2001;37:761–765.
70. Hendry JH, Akahoshi M, Wang LS, Lipshultz SE, Stewart FA, Trott KR. Radiation-induced cardiovascular injury. *Radiat Environ Biophys*. 2008;47:189–193. doi: 10.1007/s00411-007-0155-7
71. Seemann I, Gabriels K, Visser NL, Hoving S, te Poele JA, Pol JF, Gijbels MJ, Jansen BJ, van Leeuwen FW, Daemen MJ, Heeneman S, Stewart FA. Irradiation induced modest changes in murine cardiac function despite progressive structural damage to the myocardium and microvasculature. *Radiother Oncol*. 2012;103:143–150. doi: 10.1016/j.radonc.2011.10.011
72. Tapio S. Pathology and biology of radiation-induced cardiac disease. *J Radiat Res*. 2016;57:439–448. doi: 10.1093/jrr/rww064
73. Zidar N, Ferluga D, Hvala A, Popović M, Soba E. Contribution to the pathogenesis of radiation-induced injury to large arteries. *J Laryngol Otol*. 1997;111:988–990.
74. Kalman PG, Lipton IH, Provan JL, Walker PM, Miles JT, Yeung HP. Radiation damage to large arteries. *Can J Surg*. 1983;26:88–91.
75. Reinders JG, Heijmen BJ, Olofsen-van Acht MJ, van Putten WL, Levendag PC. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. *Radiother Oncol*. 1999;51:35–42.
76. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. *JAMA*. 1993;270:1949–1955.
77. Heidenreich PA, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, Tate DJ, Horning SJ, Hoppe RT, Hancock SL. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. *J Clin Oncol*. 2007;25:43–49. doi: 10.1200/JCO.2006.07.0805
78. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto

- R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med*. 2013;368:987–998. doi: 10.1056/NEJMoa1209825
79. Henson KE, McGale P, Taylor C, Darby SC. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. *Br J Cancer*. 2013;108:179–182. doi: 10.1038/bjc.2012.575
80. Plummer C, Henderson RD, O'Sullivan JD, Read SJ. Ischemic stroke and transient ischemic attack after head and neck radiotherapy: a review. *Stroke*. 2011;42:2410–2418. doi: 10.1161/STROKEAHA.111.615203
81. De Bruin ML, Dorresteijn LD, van't Veer MB, Krol AD, van der Pal HJ, Kappelle AC, Boogerd W, Aleman BM, van Leeuwen FE. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. *J Natl Cancer Inst*. 2009;101:928–937. doi: 10.1093/jnci/djp147
82. Groarke JD, Nguyen PL, Nohria A, Ferrari R, Cheng S, Moslehi J. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. *Eur Heart J*. 2014;35:612–623. doi: 10.1093/eurheartj/eh114
83. Franklin WJ, Strickman NE, Hall RJ. Stent deployment for peripheral venous stenosis as a result of radiation therapy. *Catheter Cardiovasc Interv*. 2003;59:60–62. doi: 10.1002/ccd.10488
84. Zhou W, Bush RL, Lin PH, Lumsden AB. Radiation-associated venous stenosis: endovascular treatment options. *J Vasc Surg*. 2004;40:179–182. doi: 10.1016/j.jvs.2004.03.039
85. Fakhouri F, La Batide Alanore A, Rérolle JP, Guéry B, Raynaud A, Plouin PF. Presentation and revascularization outcomes in patients with radiation-induced renal artery stenosis. *Am J Kidney Dis*. 2001;38:302–309.
86. van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, Kooijman K, Roesink J, van der Maazen R, Darby SC, Aleman BM, van Leeuwen FE. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. *J Clin Oncol*. 2016;34:235–243. doi: 10.1200/JCO.2015.63.4444
87. Weintraub NL, Jones WK, Manka D. Understanding radiation-induced vascular disease. *J Am Coll Cardiol*. 2010;55:1237–1239. doi: 10.1016/j.jacc.2009.11.053
88. Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bergler J, Bogaert J, Davin L, Cosyns B, Coucke P, Dulgheru R, Edvardsen T, Gaemperli O, Galderisi M, Griffin B, Heidenreich PA, Nieman K, Plana JC, Port SC, Scherrer-Crosbie M, Schwartz RG, Sebag IA, Voigt JU, Wann S, Yang PC; European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance; American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2013;26:1013–1032. doi: 10.1016/j.echo.2013.07.005
89. Kamath MV, Halton J, Harvey A, Turner-Gomes S, McArthur A, Barr RD. Cardiac autonomic dysfunction in survivors of acute lymphoblastic leukemia in childhood. *Int J Oncol*. 1998;12:635–640.
90. Sharabi Y, Dendi R, Holmes C, Goldstein DS. Baroreflex failure as a late sequela of neck irradiation. *Hypertension*. 2003;42:110–116. doi: 10.1161/01.HYP.0000077441.45309.08
91. Groarke JD, Tanguturi VK, Hainer J, Klein J, Moslehi JJ, Ng A, Forman DE, Di Carli MF, Nohria A. Abnormal exercise response in long-term survivors of Hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. *J Am Coll Cardiol*. 2015;65:573–583. doi: 10.1016/j.jacc.2014.11.035
92. Adams MJ, Lipsitz SR, Colan SD, Tarbell NJ, Treves ST, Diller L, Greenbaum N, Mauch P, Lipshultz SE. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. *J Clin Oncol*. 2004;22:3139–3148. doi: 10.1200/JCO.2004.09.109
93. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Astegiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM; ESC Scientific Document Group. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC). *Eur Heart J*. 2016;37:2768–2801. doi: 10.1093/eurheartj/ehw211
94. Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, Hudson MM, Kremer LC, Landy DC, Miller TL, Oeffinger KC, Rosenthal DN, Sable CA, Sallan SE, Singh GK, Steinberger J, Cochran TR, Wilkinson JD; on behalf of the American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Basic Cardiovascular Sciences, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Radiology. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association [published correction appears in *Circulation*. 2013;128:e394]. *Circulation*. 2013;128:1927–1995. doi: 10.1161/CIR.0b013e3182a88099
95. Reed GW, Masri A, Griffin BP, Kapadia SR, Ellis SG, Desai MY. Long-term mortality in patients with radiation-associated coronary artery disease treated with percutaneous coronary intervention. *Circ Cardiovasc Interv*. 2016;9:e003483. doi: 10.1161/CIRCINTERVENTIONS.115.003483
96. Wu W, Masri A, Popovic ZB, Smedira NG, Lytle BW, Marwick TH, Griffin BP, Desai MY. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. *Circulation*. 2013;127:1476–1485. doi: 10.1161/CIRCULATIONAHA.113.001435
97. Donnellan E, Masri A, Johnston DR, Pettersson GB, Rodriguez LL, Popovic ZB, Roselli EE, Smedira NG, Svensson LG, Griffin BP, Desai MY. Long-term outcomes of patients with mediastinal radiation-associated severe aortic stenosis and subsequent surgical aortic valve replacement: a matched cohort study. *J Am Heart Assoc*. 2017;6:e005396. doi: 10.1161/JAHA.116.005396
98. Yu SC, Zou WX, Soo YO, Wang L, Hui JW, Chan AY, Lee KT, Ip VH, Fan FS, Chan AL, Wong LK, Leung TW. Evaluation of carotid angioplasty and stenting for radiation-induced carotid stenosis. *Stroke*. 2014;45:1402–1407. doi: 10.1161/STROKEAHA.113.003995
99. Bruzzaniti V, Abate A, Pinnaro P, D'Andrea M, Infusino E, Landoni V, Soriani A, Giordano C, Ferraro A, Strigari L. Dosimetric and clinical advantages of deep inspiration breath-hold (DIBH) during radiotherapy of breast cancer. *J Exp Clin Cancer Res*. 2013;32:88.
100. Pedersen AN, Korreman S, Nystrom H, Specht L. Breathing adapted radiotherapy of breast cancer: reduction of cardiac and pulmonary doses using voluntary inspiration breath-hold. *Radiother Oncol*. 2004;72:53–60.
101. Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. *Hematology Am Soc Hematol Educ Program*. 2011;2011:323–329. doi: 10.1182/asheducation-2011.1.323
102. Beck RE, Kim L, Yue NJ, Haffty BG, Khan AJ, Goyal S. Treatment techniques to reduce cardiac irradiation for breast cancer patients treated with breast-conserving surgery and radiation therapy: a review. *Front Oncol*. 2014;4:327. doi: 10.3389/fonc.2014.00327
103. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. *N Engl J Med*. 2005;353:172–187. doi: 10.1056/NEJMra044389
104. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *N Engl J Med*. 2001;344:1031–1037. doi: 10.1056/NEJM200104053441401
105. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortman CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. *N Engl J Med*. 2017;376:917–927. doi: 10.1056/NEJMoa1609324
106. Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. *Trends Cardiovasc Med*. 2013;23:104–113. doi: 10.1016/j.tcm.2012.09.008
107. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. *J Clin Oncol*. 2015;33:4210–4218. doi: 10.1200/JCO.2015.62.4718
108. Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. *J Am Coll Cardiol*. 2015;66:1160–1178. doi: 10.1016/j.jacc.2015.07.025
109. Pinkhas D, Ho T, Smith S. Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development. *Cardiooncology*. 2017;3:5. doi: 10.1186/s40959-017-0024-8
110. Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, Beckman JA, Harrison DG, Moslehi J. Mechanisms of VEGF

- (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. *Hypertension*. 2018;71:e1–e8. doi: 10.1161/HYPERTENSIONAHA.117.10271
111. Touyz RM, Lang NN, Herrmann J, van den Meiracker AH, Danser AHJ. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. *Hypertension*. 2017;70:220–226. doi: 10.1161/HYPERTENSIONAHA.117.08856
 112. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. *Circulation*. 2011;124:1687–1691. doi: 10.1161/CIRCULATIONAHA.110.992230
 113. McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OP, Sabbiseti VS, Bhatt RS, Simantov R, Choueiri TK. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. *Clin Cancer Res*. 2015;21:2471–2479. doi: 10.1158/1078-0432.CCR-14-2332
 114. Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. *Ann Oncol*. 2015;26:1128–1133. doi: 10.1093/annonc/mdv147
 115. Oshima Y, Tanimoto T, Yuji K, Tojo A. Association between aortic dissection and systemic exposure of vascular endothelial growth factor pathway inhibitors in the Japanese Adverse Drug Event Report Database. *Circulation*. 2017;135:815–817. doi: 10.1161/CIRCULATIONAHA.116.025144
 116. Ueta T, Mori H, Kunimatsu A, Yamaguchi T, Tamaki Y, Yanagi Y. Stroke and anti-VEGF therapy. *Ophthalmology*. 2011;118:2093–2093.e2. doi: 10.1016/j.ophtha.2011.06.001
 117. Jang S, Zheng C, Tsai HT, Fu AZ, Barac A, Atkins MB, Freedman AN, Minasian L, Potosky AL. Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. *Cancer*. 2016;122:124–130. doi: 10.1002/cncr.29728
 118. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. *JAMA*. 2008;300:2277–2285. doi: 10.1001/jama.2008.656
 119. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurawski D, Nguyen L, Woulfel K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. *Lancet*. 2007;370:2011–2019. doi: 10.1016/S0140-6736(07)61865-0
 120. Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. *J Clin Oncol*. 2011;29:3450–3456. doi: 10.1200/JCO.2010.34.4309
 121. Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. *JACC Heart Fail*. 2013;1:72–78. doi: 10.1016/j.jchf.2012.09.001
 122. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. *N Engl J Med*. 2013;369:722–731. doi: 10.1056/NEJMoa1303989
 123. May D, Gilon D, Djonov V, Itin A, Lazarus A, Gordon O, Rosenberger C, Keshet E. Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. *Proc Natl Acad Sci USA*. 2008;105:282–287. doi: 10.1073/pnas.0707781105
 124. Chintalgattu V, Rees ML, Culver JC, Goel A, Jiffar T, Zhang J, Dunner K Jr, Pati S, Bankson JA, Pasqualini R, Arap W, Bryan NS, Taegtmeier H, Langley RR, Yao H, Kupferman ME, Entman ML, Dickinson ME, Khakoo AY. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. *Sci Transl Med*. 2013;5:187ra69. doi: 10.1126/scitranslmed.3005066
 125. Moslehi J, Minamishima YA, Shi J, Neuberger D, Charytan DM, Padera RF, Signoretti S, Liao R, Kaelin WG Jr. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. *Circulation*. 2010;122:1004–1016. doi: 10.1161/CIRCULATIONAHA.109.922427
 126. Bekeredjian R, Walton CB, MacCannell KA, Ecker J, Kruse F, Outten JT, Sutcliffe D, Gerard RD, Bruick RK, Shohet RV. Conditional HIF-1alpha expression produces a reversible cardiomyopathy. *PLoS One*. 2010;5:e11693. doi: 10.1371/journal.pone.0011693
 127. Uraizee I, Cheng S, Moslehi J. Reversible cardiomyopathy associated with sunitinib and sorafenib. *N Engl J Med*. 2011;365:1649–1650. doi: 10.1056/NEJMc1108849
 128. Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. *J Natl Cancer Inst*. 2008;100:282–284. doi: 10.1093/jnci/djm311
 129. Vigneau C, Lorcay N, Dolley-Hitze T, Jouan F, Arlot-Bonnemains Y, Laguerre B, Verhoest G, Goujon JM, Belaud-Rotureau MA, Rioux-Leclercq N. All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARE study. *Nephrol Dial Transplant*. 2014;29:325–332. doi: 10.1093/ndt/gft465
 130. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest*. 2003;111:649–658. doi: 10.1172/JCI17189
 131. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, Hacker MR, Rhee JS, Mitchell J, Mahmood F, Hess P, Farrell C, Koullis N, Khankin EV, Burke SD, Tudorache I, Bauersachs J, del Monte F, Hilfiker-Kleiner D, Karumanchi SA, Arany Z. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. *Nature*. 2012;485:333–338. doi: 10.1038/nature11040
 132. Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME. Imatinib attenuates diabetes-associated atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2004;24:935–942. doi: 10.1161/01.ATV.0000124105.39900.db
 133. Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G, Levato L, Giles FJ, Dombret H, Mirault T, Labussière H, Lindhorst R, Haverkamp W, Buschmann I, Dörken B, le Coutre PD. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. *Leukemia*. 2013;27:1316–1321. doi: 10.1038/leu.2013.70
 134. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C, Perros F, O'Callaghan DS, Jaïs X, Tubert-Bitter P, Zalcman G, Sitbon O, Simonneau G, Humbert M. Pulmonary arterial hypertension in patients treated by dasatinib. *Circulation*. 2012;125:2128–2137. doi: 10.1161/CIRCULATIONAHA.111.079921
 135. Dahlén T, Edgren G, Lambe M, Höglund M, Björkholm M, Sandin F, Sjölander A, Richter J, Olsson-Strömberg U, Ohm L, Bäck M, Stenke L; Swedish CML Group and the Swedish CML Register Group. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. *Ann Intern Med*. 2016;165:161–166. doi: 10.7326/M15-2306
 136. Li W, Garcia D, Cornell RF, Gailani D, Laubach J, Maglio ME, Richardson PG, Moslehi J. Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review. *JAMA Oncol*. 2017;3:980–988. doi: 10.1001/jamaoncol.2016.3350
 137. Valsami S, Ruf W, Leikauf MS, Madon J, Kaech A, Asmis LM. Immunomodulatory drugs increase endothelial tissue factor expression in vitro. *Thromb Res*. 2011;127:264–271. doi: 10.1016/j.thromres.2010.11.018
 138. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Housseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Brinchen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. *Leukemia*. 2008;22:414–423. doi: 10.1038/sj.leu.2405062
 139. Callahan MK, Postow MA, Wolchok JD. Targeting T cell co-receptors for cancer therapy. *Immunity*. 2016;44:1069–1078. doi: 10.1016/j.immuni.2016.04.023
 140. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Ura WJ. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. 2010;363:711–723. doi: 10.1056/NEJMoa1003466

141. Läubli H, Hench J, Stanczak M, Heijnen I, Papachristofilou A, Frank S, Zippelius A, Stenner-Liewen F. Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. *J Immunother Cancer*. 2017;5:46. doi: 10.1186/s40425-017-0249-y
142. Gambichler T, Strutzmann S, Tannapfel A, Susok L. Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade. *BMC Cancer*. 2017;17:327. doi: 10.1186/s12885-017-3313-6
143. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch ES, Deering RP, Olenchok BA, Lichtman AH, Roden DM, Seidman CE, Koralknik JJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ. Fulminant myocarditis with combination immune checkpoint blockade. *N Engl J Med*. 2016;375:1749–1755. doi: 10.1056/NEJMoa1609214
144. Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with cancer immunotherapies. *Curr Cardiol Rep*. 2017;19:21. doi: 10.1007/s11886-017-0835-0
145. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wieszorek J, Go WY. Axicabtagene ciloleucel CAR t-cell therapy in refractory large B-cell lymphoma. *N Engl J Med*. 2017;377:2531–2544. doi: 10.1056/NEJMoa1707447
146. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneis MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Tarant J, Leung M, Mueller KT, Zhang Y, Sen K, Lebowitz D, Pulsipher MA, Grupp SA. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med*. 2018;378:439–448. doi: 10.1056/NEJMoa1709866
147. Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. *Mol Ther Oncolytics*. 2016;3:16011. doi: 10.1038/mto.2016.11
148. Grundy SM, Cleeman JJ, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement [published corrections appear in *Circulation*. 2005;112:e297 and *Circulation*. 2005;112:e298]. *Circulation*. 2005;112:2735–2752. doi: 10.1161/CIRCULATIONAHA.105.169404
149. Huggins C. Prostatic cancer treated by orchiectomy; the five year results. *J Am Med Assoc*. 1946;131:576–581.
150. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. *J Clin Oncol*. 2006;24:4448–4456. doi: 10.1200/JCO.2006.06.2497
151. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer [published correction appears in *J Natl Cancer Inst*. 2012;104:1518–1523]. *J Natl Cancer Inst*. 2010;102:39–46. doi: 10.1093/jnci/djp404
152. Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. *Eur Urol*. 2015;68:386–396. doi: 10.1016/j.eururo.2014.11.039
153. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. *JAMA*. 2011;306:2359–2366. doi: 10.1001/jama.2011.1745
154. Nguyen PL, Chen MH, Beckman JA, Beard CJ, Martin NE, Choueiri TK, Hu JC, Hoffman KE, Dosoretz DE, Moran BJ, Salenius SA, Braccioforte MH, Kantoff PW, D'Amico AV, Ennis RD. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. *Int J Radiat Oncol Biol Phys*. 2012;82:1411–1416. doi: 10.1016/j.ijrobp.2011.04.067
155. Parekh A, Chen MH, D'Amico AV, Dosoretz DE, Ross R, Salenius SA, Graham PL, Beckman JA, Beard CJ, Choueiri TK, Ennis RD, Hoffman KE, Hu JC, Ma J, Martin NE, Nguyen PL. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. *Brachytherapy*. 2013;12:415–421. doi: 10.1016/j.brachy.2013.02.005
156. Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, Hyatt AS, Basaria SS, Beard CJ, Beckman JA, Choueiri TK, D'Amico AV, Hoffman KE, Hu JC, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. *BJU Int*. 2015;116:358–365. doi: 10.1111/bju.12905
157. Haidar A, Yassin A, Saad F, Shabsigh R. Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. *Aging Male*. 2007;10:189–196. doi: 10.1080/13685530701653538
158. Smith MR, O'Malley AJ, Keating NL. Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome? *BJU Int*. 2008;101:1335–1336. doi: 10.1111/j.1464-410X.2008.07707.x
159. Saylor PJ, Keating NL, Freedland SJ, Smith MR. Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. *Drugs*. 2011;71:255–261. doi: 10.2165/11588930-000000000-00000
160. Collier A, Ghosh S, McGlynn B, Hollins G. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. *Am J Clin Oncol*. 2012;35:504–509. doi: 10.1097/COC.0b013e318201a406
161. Keating NL, Liu PH, O'Malley AJ, Freedland SJ, Smith MR. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. *Eur Urol*. 2014;65:816–824. doi: 10.1016/j.eururo.2013.02.023
162. Mohamedali HZ, Breunis H, Timilshina N, Alibhai SM. Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer. *Can Urol Assoc J*. 2011;5:28–32. doi: 10.5489/auaj.09172
163. Sağlam HS, Köse O, Kumsar S, Budak S, Adsan O. Fasting blood glucose and lipid profile alterations following twelve-month androgen deprivation therapy in men with prostate cancer. *ScientificWorldJournal*. 2012;2012:696329. doi: 10.1100/2012/696329
164. Salvador C, Planas J, Agreda F, Placer J, Trilla E, Lopez MA, Morote J. Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients. *Urol Int*. 2013;90:41–44. doi: 10.1159/000342814
165. Oka R, Utsumi T, Endo T, Yano M, Kamijima S, Kamiya N, Shirai K, Suzuki H. Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up. *Int J Clin Oncol*. 2016;21:389–396. doi: 10.1007/s10147-015-0891-7
166. Mitsuzuka K, Kyan A, Sato T, Orikasa K, Miyazato M, Aoki H, Kakoi N, Narita S, Koie T, Namima T, Toyoda S, Fukushima Y, Habuchi T, Ohyama C, Arai Y; Tohoku Evidence-Based Medicine Study Group; Michinoku Urological Cancer Study Group. Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer. *Prostate Cancer Prostatic Dis*. 2016;19:57–62. doi: 10.1038/pcan.2015.50
167. Gilbert SE, Tew GA, Bourke L, Winter EM, Rosario DJ. Assessment of endothelial dysfunction by flow-mediated dilatation in men on long-term androgen deprivation therapy for prostate cancer. *Exp Physiol*. 2013;98:1401–1410. doi: 10.1113/expphysiol.2013.073353
168. Herman SM, Robinson JT, McCredie RJ, Adams MR, Boyer MJ, Celermajer DS. Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. *Arterioscler Thromb Vasc Biol*. 1997;17:2004–2009.
169. Nguyen PL, Jarolim P, Basaria S, Zufacht JP, Milian J, Kadivar S, Graham PL, Hyatt A, Kantoff PW, Beckman JA. Androgen deprivation therapy reversibly increases endothelium-dependent vasodilation in men with prostate cancer. *J Am Heart Assoc*. 2015;4:e001914. doi: 10.1161/JAHA.115.001914
170. Patel TB. Single transmembrane spanning heterotrimeric G protein-coupled receptors and their signaling cascades. *Pharmacol Rev*. 2004;56:371–385. doi: 10.1124/pr.56.3.4
171. Patnaik A, Appleman LJ, Tolcher AV, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Peña C, Xia C, Reif S, Genvesse I, Ramanathan RK. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor,

- in patients with advanced solid tumors and non-Hodgkin's lymphomas. *Ann Oncol*. 2016;27:1928–1940. doi: 10.1093/annonc/mdw282
172. Doi T, Fuse N, Yoshino T, Kojima T, Bando H, Miyamoto H, Kaneko M, Osada M, Ohtsu A. A phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors. *Cancer Chemother Pharmacol*. 2017;79:89–98. doi: 10.1007/s00280-016-3198-0
 173. Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, Verhoef G, Linton K, Thieblemont C, Vitolo U, Hiemeyer F, Giurescu M, Garcia-Vargas J, Gorbachevsky I, Liu L, Koehert K, Peña C, Neves M, Childs BH, Zinzani PL. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. *Ann Oncol*. 2017;28:2169–2178. doi: 10.1093/annonc/mdx289
 174. Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. *J Clin Oncol*. 2017;35:3898–3905. doi: 10.1200/JCO.2017.75.4648
 175. Billemont B, Medioni J, Taillade L, Helley D, Meric JB, Rixe O, Oudard S. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. *Br J Cancer*. 2008;99:1380–1382. doi: 10.1038/sj.bjc.6604709
 176. Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, Drabick JJ. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. *J Oncol Pharm Pract*. 2011;17:197–202. doi: 10.1177/1078155210378913
 177. Oh JJ, Hong SK, Joo YM, Lee BK, Min SH, Lee S, Byun SS, Lee SE. Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma. *Jpn J Clin Oncol*. 2012;42:314–317. doi: 10.1093/jjco/hys002
 178. Chen J, Wang C, Han J, Luan Y, Cui Y, Shen R, Sha D, Cong L, Zhang Z, Wang W. Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma. *Expert Rev Anticancer Ther*. 2013;13:737–743. doi: 10.1586/era.13.45
 179. Lutz SZ, Ullrich A, Häring HU, Ullrich S, Gerst F. Sunitinib specifically augments glucose-induced insulin secretion. *Cell Signal*. 2017;36:91–97. doi: 10.1016/j.cellsig.2017.04.018
 180. Ono K, Suzushima H, Watanabe Y, Kikukawa Y, Shimomura T, Furukawa N, Kawaguchi T, Araki E. Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus. *Intern Med*. 2012;51:2763–2766.
 181. Martinez Marignac VL, Smith S, Toban N, Bazile M, Aloyz R. Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming. *Oncotarget*. 2013;4:2550–2566. doi: 10.18632/oncotarget.1508
 182. Deremer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. *Clin Ther*. 2008;30:1956–1975. doi: 10.1016/j.clinthera.2008.11.014
 183. Racil Z, Razga F, Drapalova J, Buresova L, Zackova D, Palackova M, Semerad L, Malaskova L, Haluzik M, Mayer J. Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia. *Haematologica*. 2013;98:e124–e126. doi: 10.3324/haematol.2013.086355
 184. Breccia M, Muscaritoli M, Gentilini F, Latagliata R, Carmosino I, Rossi Fanelli F, Alimena G. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. *Leuk Res*. 2007;31:1770–1772. doi: 10.1016/j.leukres.2007.01.024
 185. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. *J Thromb Haemost*. 2006;4:529–535. doi: 10.1111/j.1538-7836.2006.01804.x
 186. Cronin-Fenton DP, Søndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, Baron JA, Sørensen HT. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. *Br J Cancer*. 2010;103:947–953. doi: 10.1038/sj.bjc.6605883
 187. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. *Blood*. 2013;122:1712–1723. doi: 10.1182/blood-2013-04-460121
 188. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. *Arch Intern Med*. 2006;166:458–464. doi: 10.1001/archinte.166.4.458
 189. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. *J Thromb Thrombolysis*. 2016;41:3–14. doi: 10.1007/s11239-015-1311-6
 190. Imberti D, Agnelli G, Ageno W, Moia M, Palareti G, Pistelli R, Rossi R, Verso M; MASTER Investigators. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. *Haematologica*. 2008;93:273–278. doi: 10.3324/haematol.11458
 191. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. *Blood*. 2002;100:3484–3488. doi: 10.1182/blood-2002-01-0108
 192. Trujillo-Santos J, Nieto JA, Tiberio G, Piccioli A, Di Micco P, Prandoni P, Monreal M; RIETE Registry. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism: findings from the RIETE Registry. *Thromb Haemost*. 2008;100:435–439.
 193. Louzada ML, Carrier M, Lazo-Langner A, Dao V, Kovacs MJ, Ramsay TO, Rodger MA, Zhang J, Lee AY, Meyer G, Wells PS. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. *Circulation*. 2012;126:448–454. doi: 10.1161/CIRCULATIONAHA.111.051920
 194. Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M; RIETE Investigators. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer: findings from the RIETE registry. *Thromb Res*. 2013;131:24–30. doi: 10.1016/j.thromres.2012.10.007
 195. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. *J Thromb Haemost*. 2007;5:692–699. doi: 10.1111/j.1538-7836.2007.02450.x
 196. Kearon C, Akl EA, Ornelas A, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. *Chest*. 2016;149:315–352. doi: 10.1016/j.chest.2015.11.026
 197. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. *N Engl J Med*. 2003;349:146–153. doi: 10.1056/NEJMoa025313
 198. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. *Arch Intern Med*. 2002;162:1729–1735.
 199. Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. *JAMA*. 2015;314:677–686. doi: 10.1001/jama.2015.9243
 200. Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. *Chest*. 2015;147:475–483. doi: 10.1378/chest.14-0402
 201. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. *N Engl J Med*. 2018;378:615–624. doi: 10.1056/NEJMoa1711948
 - 201a. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). *J Clin Oncol*. 2018;36:2017–2023.
 - 201b. McBane RD, Wysokinski WE, Le-Rademacher J, Ashrani AA, Tafur AJ, Gundabolu K, Perez-Botero J, Perepu U, Anderson DM, Kuzma C, Leon

- Ferre R, Henkin S, Lenz C, Loprinzi C. Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial. *Blood*. 2018;132 (suppl 1): Abstract 421. http://www.bloodjournal.org/content/132/Suppl_1/421. Accessed January 11, 2019.
202. Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. *N Engl J Med*. 2016;375:1457–1467. doi: 10.1056/NEJMra1100265
 203. Rasmussen-Torvik LJ, Shay CM, Abramson JG, Friedrich CA, Nettleton JA, Prizment AE, Folsom AR. Ideal cardiovascular health is inversely associated with incident cancer: the Atherosclerosis Risk In Communities study. *Circulation*. 2013;127:1270–1275. doi: 10.1161/CIRCULATIONAHA.112.001183
 204. Carter BD, Abnet CC, Feskanich D, Freedman ND, Hartge P, Lewis CE, Ockene JK, Prentice RL, Speizer FE, Thun MJ, Jacobs EJ. Smoking and mortality: beyond established causes. *N Engl J Med*. 2015;372:631–640. doi: 10.1056/NEJMsa1407211
 205. Danilo C, Frank PG. Cholesterol and breast cancer development. *Curr Opin Pharmacol*. 2012;12:677–682. doi: 10.1016/j.coph.2012.07.009
 206. Hu J, La Vecchia C, de Groh M, Negri E, Morrison H, Mery L; Canadian Cancer Registries Epidemiology Research Group. Dietary cholesterol intake and cancer. *Ann Oncol*. 2012;23:491–500. doi: 10.1093/annonc/mdr155
 207. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. *Science*. 2013;342:1094–1098. doi: 10.1126/science.1241908
 208. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med*. 2017;377:1119–1131. doi: 10.1056/NEJMoa1707914
 209. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ; CANTOS Trial Group. Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet*. 2017;390:1833–1842. doi: 10.1016/S0140-6736(17)32247-X
 210. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsey RC, Mermel CH, Burt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC, Kluk MJ, Henderson B, Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S, Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L, Altzman G, Wilson JG, Neuberg D, Altshuler D, Ebert BL. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med*. 2014;371:2488–2498. doi: 10.1056/NEJMoa1408617
 211. Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, Chambert K, Mick E, Neale BM, Fromer M, Purcell SM, Svantesson O, Landén M, Höglund M, Lehmann S, Gabriel SB, Moran JL, Lander ES, Sullivan PF, Sklar P, Grönberg H, Hultman CM, McCarroll SA. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *N Engl J Med*. 2014;371:2477–2487. doi: 10.1056/NEJMoa1409405
 212. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardisson D, Baber U, Mehran R, Fuster V, Danesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Ebert BL. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *N Engl J Med*. 2017;377:111–121. doi: 10.1056/NEJMoa1701719
 213. Fuster JJ, MacLaughlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, Wu CL, Sano S, Muralidharan S, Rius C, Vuong J, Jacob S, Muralidhar V, Robertson AA, Cooper MA, Andrés V, Hirschi KK, Martin KA, Walsh K. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. *Science*. 2017;355:842–847. doi: 10.1126/science.aag1381
 214. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, Dent S, Kondapalli L, Ky B, Okwuosa T, Piña IL, Volgman AS; on behalf of the American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. *Circulation*. 2018;137:e30–e66. doi: 10.1161/CIR.0000000000000556
 215. Sheng CC, Amiri-Kordestani L, Palmby T, Force T, Hong CC, Wu JC, Croce K, Kim G, Moslehi J. 21st Century cardio-oncology: identifying cardiac safety signals in the era of personalized medicine. *JACC Basic Transl Sci*. 2016;1:386–398. doi: 10.1016/j.jacbs.2016.05.008
 216. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. Tyrosine kinase inhibitors reverse type 1 diabetes in non-obese diabetic mice. *Proc Natl Acad Sci USA*. 2008;105:18895–18900. doi: 10.1073/pnas.0810246105
 217. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson DI. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. *J Clin Oncol*. 2017;35:870–877. doi: 10.1200/JCO.2016.68.7830
 218. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland Å, Storås TH, Hage TA, Røsjø H, Steine K, Geisler J, Omland T. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. *Eur Heart J*. 2016;37:1671–1680. doi: 10.1093/eurheartj/ehw022
 219. Barac A, Swain SM. Cardiac protection in HER2-targeted treatment: how should we measure new strategies? *JAMA Oncol*. 2016;2:1037–1039. doi: 10.1001/jamaoncol.2016.0283
 220. Avila MS, Ayub-Ferreira SM, de Barros Wanderley Junior MR, Cruz FDD, Gonçalves Brandao SM, Carvalho Rigaud VO, Higushi-Dos-Santos M, Hajjar LA, Filho RK, Hoff PM, Sahade M, Ferrari MSM, de Paula Costa RL, Mano MS, Bittencourt Viana Cruz CB, Abduch MC, Lofrano Alves MS, Guimaraes GV, Issa VS, Bittencourt MS, Bocchi EA. Carvedilol for prevention of chemotherapy related cardiotoxicity: the CECCY trial. *J Am Coll Cardiol*. 2018;71:2281–2290. doi: 10.1016/j.jacc.2018.02.049
 221. Stack JP, Moslehi J, Sayed N, Wu JC. Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it? [published online January 25, 2018]. *Eur Heart J*. doi: 10.1093/eurheartj/ehx811. <https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehx811/4825036?redirectedFrom=fulltext>
 222. Chintalgattu V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TL, Reddy AK, Coombes KR, Daher IN, Pati S, Patel SS, Pocius JS, Taffet GE, Buja LM, Entman ML, Khakoo AY. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. *J Clin Invest*. 2010;120:472–484. doi: 10.1172/JCI39434
 223. Snipelisky D, Park JY, Lerman A, Mulvagh S, Lin G, Pereira N, Rodriguez-Porcel M, Villarraga HR, Herrmann J. How to develop a cardio-oncology clinic. *Heart Fail Clin*. 2017;13:347–359. doi: 10.1016/j.hfc.2016.12.011
 224. Okwuosa TM, Akhter N, Williams KA, DeCara JM. Building a cardio-oncology program in a small- to medium-sized, nonprimary cancer center, academic hospital in the USA: challenges and pitfalls. *Future Cardiol*. 2015;11:413–420. doi: 10.2217/FCA.15.43
 225. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol*. 2017;35:893–911. doi: 10.1200/JCO.2016.70.5400
 226. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. *CA Cancer J Clin*. 2016;66:271–289. doi: 10.3322/caac.21349
 227. Institute of Medicine and National Research Council. *From Cancer Patient to Cancer Survivor: Lost in Transition*. Washington, DC: The National Academies Press; 2006. <https://doi.org/10.17226/11468>. Accessed December 27, 2018.
 228. Mead H, Pratt-Chapman M, Gianattasio K, Cleary S, Gerstein M. Identifying models of cancer survivorship care. *J Clin Oncol*. 2017;35(suppl):1. doi: 10.1200/JCO.2017.35.5_suppl.1
 229. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, Illiescu C, Ky B, Mayer EL, Okwuosa TM, Plana JC, Ryan TD, Rzeszut AK, Douglas PS. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. *J Am Coll Cardiol*. 2015;65:2739–2746. doi: 10.1016/j.jacc.2015.04.059
 230. Okwuosa TM, Barac A. Burgeoning cardio-oncology programs: challenges and opportunities for early career cardiologists/faculty directors. *J Am Coll Cardiol*. 2015;66:1193–1197. doi: 10.1016/j.jacc.2015.07.033
 231. US Food and Drug Administration. FDA Public Workshop: cardiovascular toxicity assessment in oncology trials. <https://www.fda.gov/Drugs/NewsEvents/ucm513031.htm>. Accessed December 27, 2018.

232. National Institutes of Health. <https://grants.nih.gov/grants/guide/pa-files/PA-16-035.html>. Accessed December 27, 2018.
233. Denlinger CS, Sanft T, Baker KS, Baxi S, Broderick G, Demark-Wahnefried W, Friedman DL, Goldman M, Hudson M, Khakpour N, King A, Koura D, Kvale E, Lally RM, Langbaum TS, Melisko M, Montoya JG, Mooney K, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Rodriguez MA, Ruddy KJ, Silverman P, Smith S, Syrjala KL, Tevaarwerk A, Urba SG, Wakabayashi MT, Zee P, Freedman-Cass DA, McMillian NR. Survivorship, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2017;15:1140–1163.
234. Creager MA, Gornik HL, Gray BH, Hamburg NM, Iobst WF, Mohler ER 3rd, White CJ. COCATS 4 Task Force 9: training in vascular medicine. *J Am Coll Cardiol*. 2015;65:1832–1843. doi: 10.1016/j.jacc.2015.03.025
235. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NJ, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M. Ponatinib in refractory Philadelphia chromosome-positive leukemias. *N Engl J Med*. 2012;367:2075–2088. doi: 10.1056/NEJMoa1205127
236. Cortes JE, Kim DW, Pinilla-Ibarz J, Ie Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. *N Engl J Med*. 2013;369:1783–1796. doi: 10.1056/NEJMoa1306494
237. Groarke JD, Cheng S, Moslehi J. Cancer-drug discovery and cardiovascular surveillance. *N Engl J Med*. 2013;369:1779–1781. doi: 10.1056/NEJMp1313140
238. Ferri N, Siegl P, Corsini A, Herrmann J, Lerman A, Benghozi R. Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. *Pharmacol Ther*. 2013;138:470–484. doi: 10.1016/j.pharmthera.2013.03.005